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ABSTRACT 
 
 
Cisplatin is the most widely used anticancer agent; however, the cellular 
pharmacokinetics are poorly understood. Cisplatin is predominantly eliminated through 
the urine via active secretion and is associated with nephrotoxicity. Currently, 
prehydration therapy is employed to prevent toxic renal side effects; however it has not 
been completely ameliorated. The studies described herein aim to determine the 
mechanism in which cisplatin enters the kidney cell from the blood and how it is 
subsequently secreted into the urine. Organic cation transporter 2 (OCT2) and ABCC2 
are highly expressed in the kidney on the basolateral and apical membrane, respectively. 
We determined the contribution of OCT2 and ABCC2 to cisplatin transport and toxicity. 
We also evaluated the contribution of genetic variation in both transporters to cisplatin 
pharmacokinetics. Our results suggest a prominent role for OCT2 in the cellular 
accumulation of cisplatin in vivo and in vitro, whereas, ABCC2 may only play a limited 
role in cisplatin pharmacokinetics in conjunction with other ABC transporters. OCT2 also 
significantly influences cisplatin induced nephrotoxicity indicating a potential for new 
preventative strategies to circumvent toxicity.  
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CHAPTER 1. INTRODUCTION 
 
 
1.1 Cisplatin 
 
 Cis-diamminedichloroplatinum (cisplatin) was first identified in 1965 when 
platinum electrodes stopped cell division in Escherichia coli cells. Preliminary testing in 
mice with a dose of 8 mg/kg showed marked tumor regression.1 Subsequent clinical trials 
indicated that cisplatin had promising antitumor activity and was approved by the FDA in 
1978.2,3 Cisplatin is used as the foundation of curative treatment in testicular and ovarian 
cancers, and is currently the most commonly used anticancer agent due to its broad 
spectrum of activity against other malignant solid tumors, including lung, head and neck, 
bladder, germ cell, endometrial, and cervical cancer.2,4,5  
 
 Evidence suggests that DNA is the major cytotoxic target of cisplatin. After it 
enters the cell, the high concentration of water and low concentration of chloride in tissue 
facilitates the aquation of cisplatin at one or both of the chloride groups thereby 
activating it.2 Cisplatin then covalently binds to the N7 position of purine bases with the 
major product (approximately 50-65 % of all adducts) being intrastrand crosslinks 
between adjacent guanine residues. A smaller portion of product includes crosslinks 
between adjacent guanine and adenine bases.3,6 These adducts cause DNA damage, such 
as unwinding or bending of the DNA template, potentially causing arrest of DNA 
synthesis and replication (Fig 1.1).7 Candidate proteins induced by platinum adducts 
include damage recognition proteins, such as, hMSH2, hMutSα, HMG1, and HMG2. 
These proteins not only recognize the DNA damage, but could, in fact, promote 
cytotoxicity. For example, HMG1 overexpression sensitizes breast tumor cells to 
cisplatin by shielding the DNA adduct from repair mechanisms. Other evidence suggests 
that DNA adducts can sequester factors important to transcription, thus preventing the 
process. Together these events can lead to cell cycle arrest, p53 activation, and finally 
apoptosis via the activation of caspase 9 and caspase 3.8  
 
 
1.2 Cisplatin Toxicity  
  
Cisplatin is a potent antitumor agent; however, it is associated with a dose-
limiting renal tubule dysfunction when administered in the conventional 3-weekly or 4-
weekly treatment regimen.5 Clinical markers of cisplatin induced acute renal failure 
include high serum creatinine, reduced serum magnesium and potassium, as well as, 
decreases in glomerular filtration rate. Although it has not been definitively defined, 
studies indicate that cisplatin nephrotoxicity can lead to long term dysfunction in 
glomerular filtration.7 Chronic nephrotoxicity causes structural damage primarily to the 
renal tubule. In particular, tubular cells in patients treated with cisplatin have cystic 
dilated tubules lined by flattened epithelium with atypical nuclei.9  
 
Cisplatin induced nephrotoxicity is characterized by tubular cell death with both 
necrosis and apoptosis contributing to the damage. The highest cisplatin concentrations  
1 
 
 
 
 
Figure 1.1 Possible Mechanisms of Cisplatin-Induced Toxicity 
 
Possible cellular pathways involved in cisplatin-induced toxicity in cells. Cisplatin enters 
the cell and forms platinum-DNA adducts, initiating a cascade of events leading to cell 
death. 
 
2 
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are found in the inner cortex and outer medulla proximal tubular cells.10 Several cell 
death pathways have been attributed to cisplatin toxicity. Death receptor tumor necrosis 
factor-α (TNF-α) receptor (TNFR) 2 has been studied and shown to be involved in 
cisplatin toxicity by ameliorating renal failure in mice deficient in TNFR 2.11 This result 
suggests an important role for TNF-α signaling. However, it is not clear whether the 
activation of the death receptors leads to apoptosis, or if the inflammation induced by 
TNF-α is the regulator of the damage.12 Recent evidence suggests that renal tubular cells, 
not infiltrating inflammatory cells, contribute to the production of TNF-α after cisplatin 
treatment.13 This mechanism could lead to the pathological conditions seen in cisplatin 
nephrotoxicity.  
 
Other factors implicated in cisplatin induced renal damage include cell cycle 
regulation and the p53 pathway. The cyclin dependent kinase (CDK) inhibitor, p21, has 
been shown to be induced during cisplatin nephrotoxicity leading to protection of the 
renal tubular cells. Mice lacking p21 suffered from a more rapid onset of renal failure 
than wildtype animals after exposure to cisplatin indicating a renoprotective role for 
p21.7,14,15  After cisplatin exposure, p53 is activated in renal tubular cells. Furthermore, 
mice lacking p53 are resistant to cisplatin induced renal failure while wildtype animals 
show an increase in p53 activity in renal tubular cells following cisplatin exposure. This 
resistance suggests an important role of p53 in tubular cell death. Events leading to p53 
activation are not fully understood, however, genotoxic stress induced by Pt-DNA 
adducts may trigger its activation.7,8,16,17  
 
Currently, hydration therapy is used in conjunction with cisplatin treatment to 
protect the kidney from cisplatin induced damage. Patients receive a prehydration, as well 
as, a posthydration infusion containing sodium chloride. In some cases, mannitol- or 
furosemide induced diuresis is used as well. This combination is thought to reduce the 
concentration of cisplatin in the kidney.7,9 As mentioned previously, the reactive aquated 
form of cisplatin is responsible for DNA damage and subsequent cell death. The increase 
in the concentration of chloride in renal tubular cells may minimize the aquation of 
cisplatin, thereby decreasing the amount of reactive cisplatin in the kidney. This 
combined therapy has been shown to decrease cases of severe renal failure in patients 
treated with cisplatin. However, approximately one-third of patients treated with cisplatin 
will still experience with cisplatin induced nephrotoxicity within the first 10 days of 
treatment.7,9 
 
 
1.3 Organic Cation Transporters Involved in Platinum Transport 
 
Due to the wide use of cisplatin in the treatment of cancer, many investigators 
have studied the route of entry for cisplatin into the cell. In previous studies using 
isolated perfused rabbit proximal tubules, cisplatin accumulation in the tubular cells was 
temperature dependent, with the S3 segment accumulating approximately 400% more 
platinum than the S1 or S2 segments at 38°C. At 23°C, cisplatin concentrations were not 
significantly higher than zero in the tubules. These results suggested that a transport 
mechanism, primarily present in the S3 segment of the tubules was responsible for 
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cisplatin accumulation in kidney cells. In subsequent experiments, the addition of 
tetraethylammonium (TEA) inhibited the transport of cisplatin into tubular cells.18 
Cisplatin has also been shown to accumulate in human renal cortex slices against a 
concentration gradient,19 and has the ability to competitively inhibit the active uptake of 
TEA by mouse kidney slices20 and by basolateral membrane vesicles from the rat renal 
cortex.21 Furthermore, cisplatin inhibits the renal clearance of organic ions from the 
basolateral site of the isolated-perfused rat kidney.5,22 All of this evidence implicates a 
significant role for an organic cation transporter (OCT) to be the primary mechanism in 
which cisplatin enters the cell.  
 
Organic cation transporters are members of the SLC22A superfamily. These 
transporters are polyspecific and are involved in the absorption and excretion of various 
endogenous and exogenous compounds. The family consists of 18 genes and includes the 
organic cation transporters (OCTs), organic cation/carnitine transporters (OCTNs), and 
organic anion transporters (OATs).23,24  Most of the members share a common membrane 
topology consisting of a predicted 12 α-helical transmembrane domains and two 
hydrophilic loops.23,25 Although they share common structure, the transporters in the 
SLC22A family show differential tissue distribution (Fig 1.2). The genes encoding the 
three organic cation transporters (SLC22A1-3) are all located in a cluster on chromosome 
6.23-25  
 
 
1.3.1 Organic cation transporter 1 (OCT1) 
 
Organic cation transporter 1 was first cloned in the rat in 1994. It is primarily 
expressed on the sinusoidal membrane of hepatocytes. However, in rodents it is 
expressed on the basolateral membrane of proximal tubules and enterocytes. OCT1 
typically transports organic cations, but other charged molecules and weak bases can also 
be transported. The main function of OCT1 is believed to be the transport of compounds 
through the sinusoidal membrane leading to the excretion of the compound.26 
 
Transport of cisplatin via OCT1 has been previously investigated yielding 
controversial results. In HEK293 cells transiently transfected with human OCT1 or rat 
Oct1, platinum uptake was not significantly different from the empty vector control.27,28 
However,  other investigators showed higher cellular accumulation of cisplatin in MDCK 
cells transfected with human OCT1 when compared to the empty vector control.29 The 
different cell lines, as well as, different experimental conditions could explain the 
inconsistencies within these experiments. As mentioned previously, OCT1 is primarily 
found on the human hepatocytes, indicating that its role in cisplatin clearance is most 
likely limited.  
 
 
1.3.2 Organic cation transporter 2 (OCT2) 
 
Organic cation transporter 2 was also first identified in the rat in 1996. It is 
primarily located on the basolateral surface of renal proximal tubules, particularly on the
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Figure 1.2 Renal and Hepatic Transporter Expression 
 
Expression of solute carrier and ABC transporters in human kidney and liver. Human OCT2 is predominantly expressed on the 
basolateral surface of kidney proximal tubules, whereas, OCT1 is expressed on human hepatocytes.  
 
S2 and S3 segments with low level expression in the brain. Previously identified OCT2 
substrates include TEA, MPP,  and cimetidine.25 In rats, OCT2 expression is dependent 
on gender and can be regulated by testosterone.25,30 OCT2 mediates the first step in renal 
elimination of compounds and may mediate the intracellular concentrations of 
monoamine neurotransmitters in the brain.25  
 
OCT2 transport of cisplatin has been evaluated; although, inconsistent results 
have been published.27-30 Currently, the role of OCT2 in cisplatin transport and toxicity is 
not well understood. Furthermore, several single nucleotide polymorpshisms (SNPs) have 
been identified in OCT231 (Table 1.1); however, the functional consequence of these 
SNPs to cisplatin transport has yet to be fully elucidated.  
 
Due to the localization of OCT2 on the basolateral membrane of renal proximal 
tubules it is a putative candidate for cisplatin transport into the kidney.  
 
 
1.4 ABCC2 (MRP2) Involvement in Cisplatin Efflux 
 
Multidrug resistance-associated proteins were first implicated in the efflux of 
cisplatin after the observation that Pt-conjugated glutathione efflux is ATP dependent.23 
Subsequently, ABCC1 was isolated in cells that were cisplatin resistant with high levels 
of intracellular glutathione. Further studies indicated no relationship between ABCC1 
expression and cisplatin cytotoxicity and accumulation in non-small cell lung cancer cell 
lines. ABCC1 is not expressed in the kidney, and therefore it is unlikely to be important 
in cisplatin clearance.23 Subsequently, ABCC2 (MRP2) was identified as an ATP 
dependent conjugate export pump with sequence identity very similar to ABCC1. This 
transporter is localized on the apical membrane of hepatocytes and renal proximal 
tubules. Due to the localization, the main function of ABCC2 is in the terminal phase of 
detoxification. Many substrates have been identified for ABCC2 including organic anions 
and glutathione S-conjugates of lipophilic substances.32 
 
 In renal cells, cisplatin forms glutathione S-conjugates before being secreted into 
the urine. Therefore it is tempting to speculate that ABCC2 may be involved in the efflux 
of cisplatin from the renal tubules. Previous investigations have suggested ABCC2 
involvement. For example, increased ABCC2 levels have been found in multiple cisplatin 
resistant cell lines23 and cisplatin resistance increased with the transfection of ABCC2 
into HEK293 and MDCK cells.33 Expression of ABCC2 was associated with cisplatin 
resistance in patients with resected colon cancer.23,34    
 
 
1.5 ABCC2 Single Nucleotide Polymorphisms 
 
 Several SPNs have been identified in ABCC2 that may contribute to functional 
changes in the transporter35,36 (Table 1.2). However, the importance of these SNPs has 
not been evaluated for cisplatin clearance.  
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Table 1.1 Nonsynonymous single nucleotide polymorphisms identified in human OCT2  
 
Gene  
Position 
Region Reference 
Allele 
Variant  
Allele 
Amino Acid 
Change 
160 Exon1  C T Pro54Ser  
     
481 Exon 2 T C Phe161Leu  
     
493 Exon 2 A G Met165Val  
     
495 Exon 2 G A Met165Ile  
     
808 Exon 4 G T Ala270Ser 
     
890 Exon 5 C G Ala297Gly  
 
1198 Exon 7 C T Arg400Cys  
     
1294 Exon 8 A C Lys432Gln  
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Table 1.2 Single nucleotide polymorphisms in ABCC2 
 
Gene  
Position 
Region Reference 
Allele 
Variant  
Allele 
Amino Acid 
Change 
-1549 5’-flanking G A - 
     
-1019 5’-flanking A G - 
     
-24 5’-UTR C T - 
     
1249 Exon 10 G A Val417Ile 
     
-34 Intron 26 T C - 
     
3972 Exon 28 C T - 
     
4544 Exon 32 G A Cys1515Tyr 
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1.6 Scope and Objective of Dissertation 
 
Previous literature has indicated the importance of potential transporters in the 
cellular accumulation and subsequent efflux of cisplatin. However, a definitive 
mechanism has yet to be elucidated. This study sought to identify the primary mechanism 
by which cisplatin is transported through the cell, as well as, the role of transporters in the 
renal toxicity of cisplatin. It was hypothesized that organic cation transporter 2 mediates 
the cellular transport, pharmacokinetics, and toxicity of cisplatin. Specifically, the 
objectives were as follows:  
 
A. Elucidated the role of organic cation transporter 2 in the cellular uptake of 
cisplatin by creating a stable cell model expressing OCT2. Using this in vitro 
system, the transport and inhibition properties were established.  
 
B. Determined the effects of OCT2 and ABCC2 expression and genetic variation 
on cisplatin pharmacokinetics and toxicity using knockout animal models and 
patient samples. Animal models deficient in the mouse orthologue transporters 
Oct1, Oct2, both Oct1/2, and Abcc2 were assessed to determine the 
contribution these transporters play in the urinary excretion and plasma 
pharmacokinetics of cisplatin. Cisplatin-induced toxicity was also evaluated in 
these mice. Previous investigators have reported changes in gene expression 
after cisplatin treatment, therefore using microarray technology, gene 
expression changes in the kidney of wildtype and knockout mice were 
assessed after cisplatin treatment. To further understand the importance of 
OCT2 and ABCC2 in cisplatin pharmacokinetics, genetic variation in both 
genes was evaluated to identify potential associations with cisplatin 
pharmacokinetics in patients. 
  
C. Evaluated the role of OCT2 and ABCC2 in tumor sensitivity by studying the 
expression and genetic variation in the NCI 60 tumor cell lines. OCT2 
expression was also determined in human tumor tissue. In order to understand 
the importance of OCT2 and ABCC2 to cisplatin tumor efficacy, expression 
of these transporters was determined in a variety of tumor samples, including 
the NCI 60 tumor cell lines. 
* Portions of this chapter adapted with permission. Filipski, K.K., Loos, W.J., Verweij, J., & Sparreboom, A. Interaction of cisplatin 
with the human organic cation transporter 2. Clin Cancer Res 14, 3875-3880 (2008). 
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CHAPTER 2. INTERACTION OF CISPLATIN WITH THE HUMAN ORGANIC 
CATION TRANSPORTER 2* 
 
 
2.1 Introduction 
 
Cis-diamminedichloroplatinum (cisplatin) is a commonly used anticancer drug 
with a broad spectrum of activity against malignant solid tumors, including lung, head 
and neck, bladder, germ cell, ovarian, endometrial, and cervical cancer.4,37 Cisplatin is 
predominantly eliminated in urine by renal secretion in the proximal tubules.4  Previous 
investigations have demonstrated that cisplatin accumulates in human renal cortex slices 
against a concentration gradient,19 and that cisplatin competitively inhibits the active 
uptake of the cation tetraethylammonium (TEA) by mouse kidney slices20 and by 
basolateral membrane vesicles from the rat renal cortex.21  Furthermore, cisplatin inhibits 
the renal clearance of organic ions from a basolateral site in the isolated-perfused rat 
kidney.22  These findings suggest that an organic cation transporter (OCT) likely 
mediates the cellular uptake of cisplatin.   
 
The expression of the OCT2 transporter is particularly high at the basolateral 
membrane of renal tubular epithelial cells, and this solute carrier is considered a major 
transporter in the active secretion of organic cations in the kidney.  The aim of the present 
study was to determine the contribution of OCT2 to cisplatin transport in vitro. Taking 
into consideration previously reported studies, we hypothesize that OCT2 will be the 
primary regulator of cisplatin transport into cells. 
 
 
2.2 Materials and Methods 
 
 
2.2.1 Materials  
 
 The Flp-In transfection system, Dulbecco’s Modified Eagle’s Medium (DMEM), 
phosphate-buffered saline (PBS), Lipofectamine 2000, hygromycin, zeocin, Opti-MEM 
reduced serum medium, TRIzol, Superscript III first strand synthesis system,  and fetal 
bovine serum were all obtained from Invitrogen (Carlsbad, CA).  The human full length 
cDNA clone of OCT2 was purchased from Origene (Rockville, MD).  American 
Radiolabeled Chemicals (St. Louis, MO) provided 14C-TEA, and Sigma Chemical Co. 
(St. Louis, MO) provided cisplatin.   
 
 
2.2.2 Cell culture and transfection 
 
 The Flp-In transfection system was used to produce stably transfected cells 
expressing OCT2.  The full length OCT2 cDNA clone was inserted into the 
pcDNA5/FRT (pcDNA5/FRT/OCT2) vector and transfected into HEK293 cells  
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containing an integrated FRT site.  Cells were seeded in 10 mL of DMEM with 10% fetal 
bovine serum (complete DMEM).  Opti-MEM I reduced serum medium was used for the 
transfection with 1 µg of pcDNA5/FRT/OCT2 (FLP-OCT2) or pcDNA5/FRT (empty 
vector), 9 µg of pOG44 and 20 µL of Lipofectamine 2000.  After 24 hours, medium was  
replaced with complete DMEM containing hygromycin B (100 µg/mL).  Medium was 
subsequently changed every 2-3 days.  Circular colonies were visible 2 weeks after 
transfection.  Cells were collected and re-seeded in either fresh complete DMEM 
containing hygromycin B, or complete DMEM containing zeocin (100 µg/mL) to test for 
zeocin sensitivity.  Cells were maintained at 37ºC in a humidified atmosphere with 5% 
CO2 and were split 1:10 every five days. 
 
 
2.2.3 RNA extraction, cDNA synthesis and RT-PCR analysis 
 
RNA was extracted from FLP-OCT2 and empty vector cells using the TRIzol 
reagent, and was reverse transcribed using the Superscript III first strand synthesis system 
according to the manufacturer’s recommendations. Gene transcripts were quantified 
using SYBR green PCR mastermix.  Primers were designed as previously described.38 
Reactions were carried out in 25-µL volumes using the following PCR parameters: 95ºC 
for 15 min, 40 cycles of 94ºC for 30 s, 60ºC for 30 s, and 72ºC for 30 s, followed by 
dissociation cycles.  Each reaction was carried out in triplicate, and transcripts of each 
sample were normalized to the housekeeping gene, GAPDH. 
 
 
2.2.4 Cellular uptake 
 
All uptake experiments were performed on monolayer cultures in 6-well plates at 
37ºC.  Briefly, monolayers were washed once with warm PBS, then DMEM containing 
14C-TEA (5 µM) was added to the cells to initiate uptake.  After a 5-min incubation, 
uptake was halted by removing the medium and washing the cells with ice-cold PBS.  
Cells were collected and solubilized in sodium hydroxide (1 N).  Radioactivity was 
assessed by liquid scintillation counting, and protein concentrations were measured using 
a bicinchoninic acid (BCA) protein-assay kit (Pierce Biotechnology, Rockford, IL).  For 
transport inhibition assays, cells were pre-incubated with increasing concentrations of 
cisplatin (up to 1000 µM) for 15 min.  Cells were washed with PBS and then incubated 
for 10 min in medium containing cisplatin and 14C-TEA (2 µM).  
 
 To determine if active uptake facilitated cisplatin transport, FLP-OCT2 and empty 
vector cells were treated with cisplatin (500 µM) at 4°C or 37°C. For measurements of 
cellular accumulation of cisplatin, FLP-OCT2 and empty vector cells were washed with 
warm PBS and treated with cisplatin (500 µM) in DMEM at pH 6, 7.4, or 8.  A 
preliminary analysis revealed that the uptake of cisplatin was linear for at least 30 min 
(data not shown), and therefore subsequent experiments were performed using 30 min 
incubation periods.  Concentration-dependent assays were carried out in DMEM 
containing cisplatin at concentrations up to 1000 µM.  After incubation, cells were 
washed twice with ice-cold PBS and collected.  Next, cells were solubilized with nitric 
acid (0.2%), and total platinum was measured using flameless atomic absorption 
spectrometry using a validated method. Briefly, 20 µL samples were injected in duplicate 
into a Perkin Elmer AAnalyst 600 atomic absorption spectrometer (Perkin Elmer, 
Norwalk, CT) with Zeeman background correction to measure platinum content.  Peak 
area measurements were performed at a wavelength of 265.9 nm with a slit width of 0.7 
nm.  Drug concentrations were determined using a linear-least squares regression analysis 
through linear calibration curves prepared in drug free nitric acid (0.2%).  Protein 
measurements were done using the BCA protein assay kit. 
 
 Pt-DNA adduct experiments were done on monolayer cultures in 100 mm dishes 
with cells seeded in 10 mL DMEM. Cells were treated with cisplatin (500 µM) in 
DMEM for 30 min.39 Cells were washed twice with ice-cold PBS and DNA was isolated 
as described previously. DNA concentrations were determined spectrophotometrically 
using the ND-1000 NanoDrop (NanoDrop Technologies) and total platinum was 
determined using the method described above. 
 
 
2.2.5 Statistical considerations 
 
Data are presented as mean and SEM, unless stated otherwise.  Statistical analyses 
were performed using a two-tailed t-test, and P values of less than 0.05 were considered 
to be statistically significant.  Calculations were performed using the software packages 
Number Cruncher Statistical Systems, version 2005 (NCSS, J. Hintze, Kaysville, UT) 
and GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA). 
 
 
2.3 Results 
 
 
2.3.1 Characterization of OCT2 overexpressed cells 
 
Expression of SLC22A2 was 36-fold higher in the FLP-OCT2 cells compared to 
the vector control cells (Fig 2.1A). Transport of the typical organic cation 14C-TEA was 
77-fold higher in the FLP-OCT2 cells when compared to vector control cells (Fig 2.1B). 
Therefore, these cells were considered to express a functional transporter and were 
suitable for subsequent experiments.  
 
 
2.3.2 Transport studies with cisplatin 
 
To determine if cisplatin is recognized as a substrate for OCT2, we first evaluated 
the effect of cisplatin on the cellular accumulation of 14C-TEA.  Cisplatin had a 
significant inhibitory effect on the transport of 14C-TEA (2 µM) in FLP-OCT2 cells, and 
no effect on the vector control cells (Fig 2.2).  We then examined the transport of 
cisplatin itself, and found that it was temperature dependent (Fig 2.3) and saturable in the 
FLP-OCT2 cells, with an apparent Michaelis-Menten constant of approximately 34 μM  
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Figure 2.1 Characterization of FLP-OCT2 Cells 
 
(A) mRNA levels of SLC22A2 in vector control cells and FLP-OCT2 cells as determined 
by real time RT-PCR. Graphs show expression of SLC22A2 normalized to GAPDH. (B) 
The uptake of 14C-TEA in vector control cells and FLP-OCT2 cells. Cells were incubated 
with 5 µM 14C-TEA for 5 min. Each bar represents the mean ± SEM of 3 independent 
experiments. 
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Figure 2.2 Cisplatin Inhibits the Uptake of TEA in FLP-OCT2 Cells 
 
Inhibitory effect of cisplatin on 14C-TEA transport in vector control cells and FLP-OCT2 
cells. Each bar represents the mean ± SEM of 3 independent experiments. 
 
 
 
 
 
 
 
 
 
 
14 
 
 
 
Figure 2.3 Temperature Dependent Uptake in FLP-OCT2 Cells 
 
Comparative uptake of 500 µM cisplatin in vector control and FLP-OCT2 cells at 4°C 
and 37°C. Each bar represents the mean ± SEM of 3 independent experiments.  
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(Fig 2.4A).  After incubation with 500 µM cisplatin for 30 min, the platinum 
accumulation in FLP-OCT2 cells compared to the vector control cells was about 4-fold 
higher (P < 0.0001) at neutral pH (Fig 2.4B) and uptake is decreased as the pH increases 
(Fig 2.4C). FLP-OCT2 cells also had a significantly higher (P = 0.0023) amount of Pt-
DNA adducts when compared with vector control cells (Fig 2.5) suggesting that cisplatin 
is itself transported by OCT2 and not just binding to the protein. 
 
 
2.4 Discussion 
 
It has recently been suggested that human OCT2 and its rodent orthologue may 
play a critical role in the cellular transport of cisplatin.28,40  However, at least one other 
report suggests that OCT2 is not a primary transporter handling cisplatin.29  To address 
these inconsistencies, we produced a stably transfected OCT2 cell line, and performed a 
detailed characterization of gene overexpression and transport function.  These 
transfected cells not only exhibited an increase in the intracellular accumulation of 
platinum following exposure to cisplatin (approximately 4-fold), but cisplatin almost 
completely inhibited the uptake of TEA, a known OCT2 substrate.  These results 
unequivocally indicate an important role for OCT2 in the transport of cisplatin.  
 
Although this study suggests an important contribution of OCT2 to the cellular 
uptake of cisplatin in vitro, the mechanisms by which cisplatin is eventually secreted 
from renal tubular cells into the lumen, and how this process is affecting the urinary 
excretion of cisplatin are still unclear.  A number of transporters previously implicated in 
cisplatin transport, including ABCC2 (MRP2, cMOAT)41 and two members of the 
multidrug and toxin extrusion family (MATE1 and MATE2-K),28 are highly expressed on 
the luminal side of renal tubules.  Our current work is thus further focused on the 
dynamic interplay between OCT2 and a number of suspected efflux carriers in the 
context of cisplatin transport using mammalian expression models. 
 
In conclusion, this study suggests that OCT2 is a primary regulator of cisplatin 
transport, but additional studies are necessary to elucidate its role in vivo.  
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Figure 2.4 Cisplatin Uptake in FLP-OCT2 Cells  
 
(A) Concentration dependent cisplatin uptake in FLP-OCT2 cells. (B) Comparative 
uptake of 500 µM cisplatin in vector control cells and FLP-OCT2 cells at neutral pH. (C) 
pH dependence of cisplatin uptake in FLP-OCT2 cells. Each point or bar represents the 
mean ± SEM of 3 independent experiments.  
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Figure 2.5 Pt-DNA Adducts in FLP-OCT2 Cells after Cisplatin Treatment 
 
Pt-DNA adducts in vector control cells and FLP-OCT2 cells after incubation with 500 
µM cisplatin. Each bar represents the mean ± SEM of 3 independent experiments 
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CHAPTER 3. CONTRIBUTION OF ORGANIC CATION TRANSPORTER 2 TO 
CISPLATIN INDUCED NEPHROTOXICITY IN MICE  
 
 
3.1 Introduction  
 
Cisplatin is among the most widely used anticancer agents and has a broad 
spectrum of activity.  Irreversible kidney damage is an important complication of 
cisplatin treatment as it may limit further treatment or even threaten life.  This side effect 
primarily affects the S3 segment of the renal proximal tubules and occurs in one-third of 
patients despite intensive prophylactic measures.42  Furthermore, about 20% of all acute 
renal failure cases among hospitalized patients are due to cisplatin-containing 
chemotherapy.43  The exact pathogenesis of cisplatin-related nephrotoxicity remains 
unclear. Despite having been the focus of intense investigation for many decades, the 
exact pathogenesis of cisplatin-related nephrotoxicity, in which quiescent proximal 
tubular cells are selectively damaged, remains unclear.44  Recent studies have suggested 
that inflammation, oxidative stress and apoptosis probably explain part of the tissue 
injury, although the initiating event leading to tubular damage and mechanistic details of 
the drug’s renal handling are still poorly understood.45  
 
We and others have recently reported that the organic cation transporter 2 
(OCT2), encoded by the SLC22A2 gene, can actively transport cisplatin in vitro.5,29,46,47  
This transporter is predominantly expressed in human kidney at the basolateral 
membrane of renal proximal tubules, and is involved in the secretion of various cationic 
substances from the circulation into tubular cells.  All experiments to date, however, have 
assessed a putative role of OCT2 in cisplatin-related nephrotoxicity in cultured cells.  The 
continual identification of substrates for renal transporters using heterologous in vitro 
expression systems provides valuable information for predicting drug-drug and drug-
protein interactions.48 However, the well-recognized limitation of these preliminary 
determinations is that they do not indicate the true relevance of a transporter in handling a 
substrate in the context of whole-body disposition, renal and extrarenal transport, and 
glomerular filtration.  Indeed, to attribute an abnormality in normal physiology to 
transporter perturbation, the relevance of the transporter to the disposition of a drug must 
first be determined in vivo. The aim of the current investigation was to compare the 
pharmacokinetics, urinary excretion, and extent of nephrotoxicity in mice lacking the 
ortholog transporters Oct1 [Oct1 (-/-) mice], Oct2 [Oct2 (-/-) mice], or both Oct1 and 
Oct2 [Oct1/2 (-/-) mice] after treatment with cisplatin.  We hypothesize that Oct2 will be 
responsible for the renal uptake of cisplatin, and the loss of Oct2 may prevent renal 
tubule cells from damage after cisplatin treatment. 
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3.2 Materials and Methods 
 
 
3.2.1 Animal experiments 
 
 Adult (8-12 week old) male Oct1(-/-), Oct2(-/-) or Oct1/2(-/-) (Taconic) mice 
were used along with age-matched male FVB wild-type mice. Mouse genotypes from tail 
biopsies were determined using real time PCR with specific probes designed for each 
gene (Transnetyx, Cordova, TN, USA). All animals were housed and handled in 
accordance with the Institutional Animal Care and Use Committee of St. Jude Children’s 
Research Hospital. Animals were housed in a temperature controlled environment with a 
12 hour light cycle and were given a standard diet and water ad libitum.  
 
Urinary platinum excretion of cisplatin was studied in animals after they had 
acclimated to metabolic cages 5 days prior to drug administration. Baseline urine samples 
were collected sixteen hours after the onset of light, and next, mice were given a single 
intraperitoneal (i.p.) injection of cisplatin at a dose 10 mg/kg. Urine was collected 4, 24, 
48, and 72 hours after administration, diluted with nitric acid (0.2%) and immediately 
analyzed for total platinum using flameless atomic absorption spectrometry. At the end of 
the study period, mice were euthanized and tissues harvested for gene expression and 
histological examination.  
 
In separate animals, the plasma pharmacokinetics of cisplatin (10 mg/kg, i.p.) was 
determined using a terminal sampling procedure. Blood samples were collected by 
cardiac puncture after anesthesia with isoflurane in heparin-containing microtubes at 
0.25, 0.75, 1, 4, and 8 hours after drug administration. Samples were immediately 
centrifuged at 2000 × g for 10 min and plasma was removed and stored frozen until 
analysis by AAS.  
 
 
3.2.2 Determination of platinum concentrations 
 
 Total platinum was determined using an AAnalyst 600 atomic absorption 
spectrometer with Zeeman background correction (Perkin Elmer, Norwalk, CT, USA).  
Concentrations in unknown samples were interpolated on a linear calibration curves 
ranging from 0.2 to 3 μg/mL that were constructed fresh daily in the relevant matrix.  The 
percentage deviation from nominal values and the within-run and between-run precision 
of quality control samples spiked with known amounts of cisplatin were always <15%.  
Concentrations of free, protein-unbound platinum in plasma were determined as 
described.2  Pharmacokinetic parameters were calculated using PK Solutions 2.0 (Summit 
Research Services, Montrose, CO, USA). 
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3.2.3 Peripheral blood analysis 
 
 Chemistry analysis was performed on serum using a Vetscan autoanalyzer 
(Abaxis)  to determine levels of albumin, alkaline phosphatase, alanine aminotransferase, 
amylase, total bilirubin, blood urea nitrogen, calcium, phosphorus, creatinine, glucose, 
sodium, potassium, and total protein.  
 
 
3.2.4 Histological evaluation of mouse tissues  
 
Mice were humanely euthanized and the following tissues were collected: 
adrenals, bone marrow, brain, heart, kidneys, large intestine, liver, lung, lymph node, 
pancreas, reproductive tract, salivary gland, skeletal muscle, skin, small intestine, spleen, 
stomach, thymus, and thyroid.  After collection, tissues were fixed overnight in 10% 
neutral-buffered formalin.  Next, the tissues were processed routinely, embedded in 
paraffin, sectioned (4 µm) and stained with hematoxylin and eosin.  Microscopic 
evaluation was performed by an experienced veterinary pathologist blinded to the 
composition of the groups.  Toxicities, including acute renal tubular necrosis, were 
scored as ‘absent’, ‘rare’, ‘mild’, ‘moderate’ or ‘severe’. 
 
 
3.2.5 Statistical calculations 
  
Group differences in median pharmacokinetic parameters of cisplatin as a 
function of mouse genotype was evaluated using a Mann-Whitney U test.  Variability in 
serum chemistry values in the studied mouse strains as a function of treatment was 
assessed using a Kruskal-Wallis test followed by a Kruskal-Wallis Z-test.   
 
 
3.3 Results  
 
 
3.3.1 Urinary platinum excretion and cisplatin pharmacokinetics  
 
An assessment of the urinary excretion profile of cisplatin revealed that the 
cumulative percentage of the administered dose was very similar in Oct1(-/-) and  
Oct2(-/-) mice compared with wildtype mice (Fig 3.1).  Consistent with previous 
findings,49 the majority of the dose was excreted within the first 24 hours.  The lack of a 
significant impact of the individual Oct1 and Oct2 deficiencies on the elimination of 
cisplatin is in line with earlier observations made for the cationic substance 
tetraethylammonium (TEA) in the same animal models,50,51 and suggests that in the 
mouse cisplatin is recognized as a substrate by both Oct1 and Oct2.  Although mice 
express substantial levels of both Oct1 and Oct2 in the kidney, in humans there is strong 
agreement that OCT2 dominates renal organic cation transport, whereas OCT1 dominates 
hepatic organic cation transport.52  Therefore, we used Oct1/2(-/-) mice in all subsequent 
experiments as the most appropriate animal model.  
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Figure 3.1 Urinary Platinum Excretion in Oct1 (-/-) and Oct2 (-/-) Mice 
 
Effect of Oct1 and Oct2 deficiency on renal handling of cisplatin in mice. The cumulative 
excretion of cisplatin after drug administration (10 mg/kg; i.p.) was unchanged in      
Oct1 (-/-), Oct2 (-/-), and wildtype mice (n = 4-5/group). Data are shown as mean values; 
error bars represent ± standard error. 
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 At 24 hours, Oct1/2 (-/-) mice had a cumulative excretion of 45% of the 
administered dose compared to 91% in wildtype animals (P = 0.0008) and only 56% of 
the dose was recovered after 72 hours in Oct1/2 (-/-) mice. Both the rate and extent of the 
cumulative urinary excretion of cisplatin was markedly reduced in the Oct1/2(-/-) mice 
(47%; P = 0.0016) (Fig 3.2), confirming a direct role of organic cation transporters in the 
renal handling of cisplatin.  
 
The reduced renal excretion in the Oct1/2 (-/-) mice was not accompanied by 
measurable changes of cisplatin in plasma (Fig 3.3A). For example, in wildtype and 
Oct1/2 (-/-) mice we observed a Cmax of 26.7 ± 9.73 and 36.4 ± 8.47, respectively. 
Furthermore, the area under the plasma concentration curve was 50.36 µg.h/mL in  
wildtype and 54.9 µg.h/mL in Oct1/2 (-/-) mice. Unbound plasma platinum 
concentrations also were not affected (Fig 3.3B).  
 
 
3.3.2 Histopathology and serum chemistry analysis  
 
As predicted based on the excretion data, we found that severe, acute renal tubular 
necrosis was only observed in the wildtype animals (Fig 3.4).  The lesions were 
characterized by dilated tubules filled with necrotic tubular epithelial cells, cellular debris 
and proteinaceous casts, whereas the glomeruli were histologically normal.  Consistent 
with these histopathological observations, various physiologic hallmarks of cisplatin-
related nephrotoxicity in humans, such as changes in serum alkaline phosphatase, blood 
urea nitrogen and serum creatinine, were specifically altered in wildtype mice undergoing 
cisplatin treatment (Table 3.1).  Tissues other than kidney in the Oct1/2 (-/-) mice, 
including liver, brain, and pancreas, were also histologically normal (Fig 3.5), indicating 
that the impaired renal excretion in this strain does not cause exacerbated cisplatin-related 
side effects elsewhere. 
 
 
3.4 Discussion 
 
 In our previous in vitro studies, we determined that human organic cation 
transporter 2 was involved in the uptake of cisplatin into cells. To further characterize the 
interaction of cisplatin with OCT2, we examined the urinary excretion, plasma 
pharmacokinetics, and toxicity in mice lacking the mouse orthologues Oct1, Oct2, or 
both Oct1 and Oct2. Although it has been speculated for several decades that net tubular 
secretion of cisplatin may be the initiating event in renal tubular damage,45 our 
demonstration that Oct1/2 (-/-) mice exhibit impaired urinary elimination of cisplatin for 
the first time substantiates an important role of organic cation transporters in the in vivo 
renal handling of this compound.  The most plausible explanation for the observed 
differences in urinary excretion of cisplatin in Oct1/2 (-/-) mice compared with wildtype 
mice is an impaired uptake of the drug in renal tubular cells and subsequently reduced 
renal tubular secretion into urine in the knockout strain. 
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Figure 3.2 Urinary Platinum Excretion in Oct1/2 (-/-) Mice 
 
Effect of simultaneous Oct1 and Oct2 deficiency on renal handling of cisplatin in mice. 
The cumulative excretion of cisplatin was reduced in Oct1/2(-/-) mice compared to 
wildtype mice (n = 11-12/group) after drug administration (10 mg/kg; i.p.). Data are 
shown as mean values; error bars represent standard error. 
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Figure 3.3 Cisplatin Plasma Concentrations 
 
(A) Comparative concentration-time profiles of cisplatin in plasma of Oct1/2 (-/-) mice 
and wildtype mice (n = 4/group) after the administration of cisplatin (10 mg/kg; i.p.). 
Data shown as mean values with standard error along with a curve fit from a 2 
compartment model. (B) Comparative concentration-time profiles of unbound platinum 
in plasma of Oct1/2(-/-) mice and wildtype mice (n = 4/group) after the administration of 
cisplatin (10 mg/kg, i.p.). Data shown as mean values with standard error. 
 
25 
 
26 
 
 
 
Figure 3.4 Histopathology of Wildtype and Oct1/2 (-/-) Mouse Kidney 
 
Comparative cisplatin-related nephrotoxicity in (A) untreated wildtype and (B) untreated 
Oct1/2 (-/-) mice with (C) treated wildtype, and (D) treated Oct1/2 (-/-) mice 72 hours 
after the administration of cisplatin (10 mg/kg, i.p.) from representative animals. Severe 
renal tubular necrosis, characterized by dilated tubules filled with necrotic tubular 
epithelial cells, was observed in kidneys of all wildtype mice but in none of the       
Oct1/2 (-/-) mice (n = 8/group). Arrows indicate tubules. 
 
Variable    Wildtype  Oct1/2(-/-)  Wildtype  Oct1/2(-/-)  P* 
Blood urea nitrogen (mg/dL)  24 (22 – 27)  22 (18 – 28)  157 (62 – 199)** 80 (31 – 180)  0.00096 
Alkaline phosphatase (U/L)  139 (120 – 154)  138 (108 – 167)  55 (2 – 68)**  75 (51 – 91)  0.00048 
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Table 3.1 Altered serum chemistry in wildtype mice 72 hours after cisplatin administration (10 mg/kg, i.p.) 
 
     Untreated [median (range)]   Treated [median (range)] 
 
Albumin (g/dL)    3.4 (3.2 – 3.4)  3.6 (3.3 – 4.1)  3.2 (1.8 – 4.5)  3.7 (3.4 – 4.3)  0.41 
Alanine aminotransferase (U/L)  68 (50 – 98)  63 (9 – 273)  250 (108 – 493)** 139 (90 – 304)  0.018 
Amylase (U/L)    1040 (983 – 1130) 874 (802 – 1090) 2570 (1130 – 3920)** 1730 (1280 – 2040)** 0.0020 
Bilirubin (mg/dL)   0.30 (0.3 – 0.3)  0.35 (0.3 – 0.4)  0.20 ( 0.1 – 0.3)  0.30 (0.2 – 0.4)  0.070 
Calcium (mg/dL)   9.4 (9.3 – 9.9)  9.8 (9.5 – 10.1)  11.4 (7.1 – 12.7) 9.8 (9.6 – 11.7)  0.13 
Creatinine (mg/dL)   0.25 (0.20 – 0.30) 0.35 (0.20 – 0.50) 0.90 (0.40 – 1.60)** 0.45 (0.20 – 0.70) 0.0080 
Globulin (g/dL)    1.9 (1.8 – 1.9)  2.1 (1.9 – 2.4)  2.3 (1.2 – 2.8)  2.2 (1.3 – 2.6)  0.13 
Glucose (mg/dL)   215 (198 – 238)  183 (172 – 655)  149 (35 – 205)** 177 (135 – 223)  0.034 
Phosphorus (mg/dL)   8.5 (8.4 – 10.1)  9.4 (8.9 – 18.1)  15.0 (5.4 – 24.2) 6.8 (5.9 – 9.0)  0.088 
Potassium (mmol/L)   6.9 (6.8 – 8.0)  6.9 (3.0 – 7.8)  7.9 (6.8 – 9.7)  8.5 (6.8 – 9.7)  0.10 
Sodium (mmol/L)   151 (147 – 151)  152 (151 – 152)  148 (110 – 152)  152 (148 – 154)  0.054 
Total protein (g/dL)   5.3 (4.9 – 5.3)  5.6 (5.5 – 5.6)  5.6 (3.0 – 7.1)  5.6 (3.1 – 6.9)  0.19 
 
* Kruskal-Wallis test followed by a Kruskal-Wallis Z test with Bonferroni correction. 
** Different from untreated
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Figure 3.5 Histopathology of Mouse Tissue 
 
Histopathology of wildtype and Oct1/2 (-/-) mice 72 hours after the administration of 
cisplatin. All tissues were histologically normal. For each tissue type, images of wildtype 
mice are above the Oct1/2 (-/-) images.  
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 Urinary excretion of cisplatin in Oct1 (-/-) and Oct2 (-/-) mice were assessed, but 
did not show a significant difference when compared to wildtype littermates. In previous 
studies using these mice, investigators did not see a significant changes in plasma TEA 
concentrations in the single knockouts, when compared to wildtype mice.51 As mentioned 
previously, Oct1 is more highly expressed in mouse kidney cells than in human kidney 
and may have some substrate overlap with Oct2. Studies identifying rat Oct1 and human 
OCT1 as a transporter for cisplatin have been controversial.27-29 In this model, the lack of 
differences in urinary excretion in the Oct1 (-/-) and Oct2 (-/-) mice indicate at least a 
minor role for mouse Oct1 in cisplatin transport. Although OCT1 is primarily found only  
in human liver, the possible substrate overlap and high expression of mouse Oct1 in the 
kidney suggest a necessity for evaluating a double Oct1 and Oct2 knockout mouse. 
Therefore we concluded that using the Oct1/2 (-/-) mice was the best model to accurately 
assess cisplatin excretion and pharmacokinetics in mice.  
 
Urinary platinum excretion was significantly altered in Oct1/2 (-/-) with only 56% 
of the cisplatin dose recovered in the urine after 72 hours. In spite of the currently 
observed changes in renal handling of cisplatin in the Oct1/2 (-/-) mice, we found that the 
apparent plasma clearance of cisplatin and measures of systemic exposure to total 
cisplatin and unbound cisplatin was unaltered in this mouse model.  This paradox might 
be explained by the possibility that the high expression of Oct1 and Oct2 in renal tubular 
cells can directly control local drug levels, and thereby alter the urinary excretion of 
cisplatin without affecting measures of systemic exposure.  The notion that the impaired 
urinary excretion of cisplatin in the Oct1/2 (-/-) mice was not accompanied by any 
evidence of other organ damage indicates a possible shunting of the primary pathway of 
cisplatin elimination as opposed to a dramatically altered drug distribution.  A similar 
phenomenon has been reported previously for the anticancer and antirheumatic drug 
methotrexate, where deficiency of Abcc2 (Mrp2), a transporter regulating biliary 
secretion of this agent, is associated with increases in the extent of urinary excretion 
compared with wildtype mice.53  Additional investigation is required to confirm the 
possibility that cisplatin is predominantly eliminated by the hepatobiliary route in the 
Oct1/2 (-/-) mice. 
 
These studies using Oct1/2 (-/-) mice indicate a significant role for OCT2 in the 
renal handling and toxicity of cisplatin without affecting the cisplatin plasma 
concentrations.  
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CHAPTER 4. EFFECT OF CISPLATIN TREATMENT ON GENE EXPRESSION 
IN MICE 
 
 
4.1 Introduction  
 
 Cisplatin is used for the treatment of a large spectrum of cancers, but treatment is 
limited by drug induced nephrotoxicity which still affects one third of patients despite 
prophylactic hydration procedures. Drug induced renal damage typically affects the renal 
proximal tubules which are responsible for active secretion and reabsorption of 
xenobiotics and endogenous compounds. These compounds are typically transported 
across the basolateral membrane by organic cation or anion transporters, and are 
subsequently effluxed from the apical membrane by primary active transporters. 
Regulation of these transporters is vitally important for the removal of toxic compounds 
from the blood. Previous investigators have reported changes in transporter gene 
expression after treatment with various compounds.54 Furthermore, gene expression 
changes in important cellular pathways, particularly p53 signaling, after treatment with 
cytotoxic drugs has also been described.7 In this study, we evaluated the effect of 
cisplatin treatment on the gene expression of transporters in kidneys of wildtype,       
Oct1 (-/-), Oct2 (-/-), and Oct1/2 (-/-) mice.   
 
 
4.2 Materials and Methods 
 
 
4.2.1 Animals 
 
Adult (8-12 week old) male Oct1(-/-), Oct2(-/-) or Oct1/2(-/-) (Taconic) mice 
were used along with age-matched male FVB wild-type mice. Mouse genotypes from tail 
biopsies were determined using real time PCR with specific probes designed for each 
gene (Transnetyx, Cordova, TN, USA). All animals were housed and handled in 
accordance with the Institutional Animal Care and Use Committee of St. Jude Children’s 
Research Hospital. Animals were housed in a temperature controlled environment with a 
12 hour light cycle and were given a standard diet and water ad libitum. Mice were 
administered 10 mg/kg cisplatin via an i.p. injection while in metabolic cages. Kidneys 
were harvested 48 or 72 hours after drug administration. 
 
 
4.2.2 Gene expression analysis of mouse kidney 
 
RNA was extracted using the RNEasy mini kit (Qiagen, Valencia, CA, USA).  
RNA samples were amplified from 3 animals per group and then analyzed using the 
Mouse 430v2 GeneChip array (Affymetrix, Santa Clara, CA, USA). Data analysis was 
performed using a subset of genes including common drug-metabolizing enzymes, 
nuclear receptors, ATP-binding cassette transporters, and solute carrier genes. A fisher’s 
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exact test was used to identify functionally related pathways, and probability and false 
discovery rates were calculated. 
 
 
4.2.3 Cellular uptake 
 
 Human embryonic kidney 293 (HEK293) cells overexpressing human OCT6 were 
produced using the Flp-In transfection system (Invitrogen, Carlsbad, CA, USA). The full 
length OCT6 cDNA clone was inserted into the pcDNA5/FRT vector and transfected into 
HEK293 cells containing an integrated FRT site as previously described.5 HEK293 cells 
overexpressing human OAT3 were provided by Dr. Yuichi Sugiyama (Tokyo, Japan). 
Measurements of cellular accumulation of cisplatin were performed in six well plates 
with monolayer cultures at 37ºC as previously reported.5 Briefly, cell monolayers were 
washed with warm PBS and were treated with DMEM containing cisplatin (500 µM) for 
30 min. After incubation, cells were washed twice with ice cold PBS and collected. Cells 
were then solubilized with nitric acid (0.2%), and total platinum was measured using 
flameless atomic absorption spectrometry. Protein measurements were performed using a 
BCA protein assay kit (Pierce Biotechnology, Rockford, IL).  
 
 
4.3 Results 
 
 
4.3.1 Gene expression changes in Oct1 (-/-) and Oct2 (-/-) mice after cisplatin treatment 
 
 First, the gene expression changes in Oct1 (-/-), Oct2 (-/-), and wildtype animals 
were evaluated after treatment with cisplatin. Upon comparison of Oct1 (-/-) with 
wildtype gene expression, a 2-fold upregulation of Slc22a16 in Oct1 (-/-) mice was 
discovered. (Fig 4.1A). The Slc22a16 gene encodes the organic cation transporter 6 
(OCT6), but its overexpression is unlikely to affect the renal handling of cisplatin since 
the drug was not found to be a substrate of OCT6 (Fig 4.2). In contrast, the only gene that 
was significantly different in Oct2 (-/-) was Oct2 (Fig 4.1B).  
 
 
4.3.2 Gene expression changes in Oct1/2 (-/-) and wildtype mice after cisplatin treatment 
 
Microarray analysis showed that more than 4,235 and 3,334 probe sets, 
respectively, exhibited a statistically significant change in cisplatin-treated wildtype mice 
and Oct1/2 (-/-) mice compared with untreated controls.  Following correction for 
multiple hypotheses testing to limit the false discovery rate to 5%, 4,774 probe sets were 
identified, of which 4,168 had annotated biological processes, indicating that cisplatin 
treatment has a major effect on renal gene expression profiles.  A subsequent gene 
ontology analysis indicated that the most significantly perturbed physiological processes 
in wildtype and Oct1/2 (-/-) mice were the p53 signaling pathway and the cytokine-
cytokine receptor interaction pathway.  This disruption is not surprising considering the  
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Figure 4.1 Gene Expression Changes in Oct1 (-/-) and Oct2 (-/-) Mice 
 
Differential gene expression in the kidney of male Oct1 (-/-) mice (A) and Oct2 (-/-) mice 
(B) relative to wildtype FVB mice (n = 3/group) as assessed using the Affymetrix Mouse 
430v2 GeneChip array. Select genes on the volcano plot include enzymes, nuclear 
receptors, ABC transporters, and solute carriers. 
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Figure 4.2 Cisplatin Accumulation in OCT6 Overexpressing Cells 
 
Intracellular uptake of cisplatin in HEK293 cells transfected with OCT6 following 
incubation with 500 µM cisplatin for a period of 30 minutes. Data expressed relative to 
drug accumulation in cells transfected with an empty vector, which was set to 100 %. 
Bars represent mean values; error bars represent standard error. 
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important role of p53 signaling7 and cytokines55 in tubular apoptosis after administration 
of cisplatin. 
 
Before treatment, the only gene expression changes observed to be different in 
wildtype and Oct1/2 (-/-) mice were the respective gene deletions (Fig 4.3). Cisplatin 
treatment was also associated with significant changes in expression of transporter genes, 
many of which are known to be localized in renal tubular cells.  This was predominantly 
observed in samples originating from wildtype mice, suggesting that excessive 
accumulation of cisplatin in proximal tubules predisposes to these phenotypic alterations.  
Among the transporter genes, those known to be responsible for inward-directed transfer 
of molecules were typically repressed (Fig 4.4), whereas the expression of ATP-binding 
cassette transporter genes was elevated (Fig 4.5).  For example, among the most highly 
reduced genes was the organic anion transporters Oat3 (between 8- and 16-fold) which 
does not transport cisplatin (Fig 4.6), whereas the P-glycoprotein-encoding Abcb1b gene 
was increased up to 28-fold.  The currently observed changes in expression of renal 
xenobiotic transporter genes in wildtype FVB mice following treatment with cisplatin are 
consistent with prior findings in male C57BL/6J mice.54 
 
It is interesting to note, that the copper transporter (Ctr1), which has been 
previously identified as a potential mechanism of cisplatin transport,56 was unchanged in 
both wildtype and Oct1/2 (-/-) mice after treatment (Fig 4.7). This result may indicate a 
limited involvement for this transporter in our particular model. 
 
 
4.4 Discussion 
 
 In this study we evaluated the expression changes of common drug metabolizing 
enzymes, ABC transporters and solute carrier genes after treatment of cisplatin in mouse 
kidney. Previously we reported a significant decrease in urinary platinum excretion in 
Oct1/2 (-/-) mice compared to wildtype animals after cisplatin treatment. The most 
plausible explanation for the observed differences in urinary excretion of cisplatin in 
Oct1/2 (-/-) mice compared with wildtype mice is an impaired uptake of the drug in renal 
tubular cells and subsequently reduced renal tubular secretion into urine in the knockout 
strain. Fifty six percent of the dose is still recovered in the urine of Oct1/2 (-/-) mice, 
suggesting a potential change in the gene expression of transporters at the basolateral side 
of the renal proximal tubule. Gene expression in the kidneys of Oct1 (-/-) and Oct2 (-/-) 
mice was not significantly different from wildtype animals after treatment, except for the 
upregulation of the organic cation transporter Slc22a16; however this is not a transporter 
for cisplatin.  
 
 Gene expression in wildtype and Oct1/2 (-/-) mice was unchanged before cisplatin 
treatment, but significant changes were observed in the kidney of wildtype animals after 
cisplatin administration. For example, an up to 11-fold downregulation of organic anion 
transporter Slc22a8 and an upregulation of Abcb1b was observed.  However, neither of 
these transporters has been shown to transport cisplatin in vitro, indicating that the gene 
expression changes may have been in relation to the severe toxicity observed in wildtype  
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Figure 4.3 Gene Expression in Untreated Wildtype and Oct1/2 (-/-) Mice 
 
Differential gene expression in the kidney of male Oct1/2 (-/-) mice relative to wildtype 
mice (n = 3/group) as assessed using the Affymetrix Mouse 430v2 GeneChip array. 
Select genes on the volcano plot include enzymes, nuclear receptors, ABC transporters, 
and solute carriers. 
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Figure 4.4 Solute Carrier Gene Expression Changes in Mice after Cisplatin Treatment 
 
Gene expression changes in solute carriers in the kidney of male Oct1/2(-/-) and wildtype 
mice (n = 3/group) following treatment with cisplatin (10 mg/kg; i.p.) as determined by 
the Affymetrix mouse 430v2 genechip microarray. Data expressed as fold change versus 
untreated control in samples obtained at 72 hours after drug administration.  
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Figure 4.5 Differential Expression in ABC Transporters after Cisplatin Treatment  
 
Gene expression changes in ABC transporters in the kidney of male Oct1/2(-/-) and 
wildtype mice (n = 3/group) following treatment with cisplatin (10 mg/kg; i.p.) as 
determined by the Affymetrix mouse 430v2 genechip microarray. Data expressed as fold 
change versus untreated control in samples obtained at 72 hours after drug 
administration. 
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Figure 4.6 Cisplatin Uptake in OAT3 Expressing Cells  
 
The intracellular uptake of methotrexate (MTX), a positive control, and platinum (Pt) was 
assessed in HEK293 cells transfected with human OAT3 and mouse Oat3 following 
incubation of 10 µM methotrexate or 500 µM cisplatin for a period of 30 minutes. 
Transport of cisplatin by OCT2 is shown for comparative purposes. Date expressed 
relative to drug accumulation in cells transfected with an empty vector, which was set to 
100%. Data shown as mean values with standard error. 
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Figure 4.7 Ctr1 Expression 
 
Gene expression changes in the copper transporter 1 (Ctr1; Slc31a1) in the kidney of 
male Oct1/2 (-/-) and wildtype mice (n = 3/group) before and after treatment with 
cisplatin (10 mg/kg, i.p.) as determined by the Affymetric mouse 430v2 genechip 
microarray.  Samples were obtained at 72 hours after drug administration. 
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kidneys and not cisplatin transport. A recent investigation indicated that the copper 
transporter 1 (Ctr1; Slc31a1) is localized on the basolateral side of both proximal and 
distal tubular cells in the kidney of C57BL/6 mice, and that downregulation of Ctr1 
expression by small interfering RNA was associated with decreased cisplatin uptake in 
vitro.57  In this context, it is interesting to note that the expression of Slc31a1 was not 
different in kidney samples obtained from wildtype mice and Oct1/2 (-/-) mice, and was 
also not affected by treatment with cisplatin. This result indicates a limited involvement 
for the Ctr1 transporter in the observed pharmacokinetic and pharmacodynamic changes 
in our particular mouse model. 
 
 Gene expression changes observed in the wildtype mice could indicate possible 
mechanisms to counteract the effects of cisplatin. It would be interesting to evaluate the 
gene expression changes in the liver Oct1/2 (-/-) mice after cisplatin treatment to identify 
any possible changes that could contribute to an increase in cisplatin elimination. In line 
with our previous toxicity and pharmacokinetic results, cisplatin did not significantly 
alter gene expression in the kidney of Oct1/2 (-/-) mice, but did dramatically change 
expression in wildtype animals.  
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* Portions of this chapter adapted with permission. Filipski, K.K., Loos, W.J., Verweij, J., & Sparreboom, A. Interaction of cisplatin 
with the human organic cation transporter 2. Clin Cancer Res 14, 3875-3880 (2008). 
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CHAPTER 5. GENETIC VARIATION IN ORGANIC CATION TRANSPORTER 
2 AND CISPLATIN PHARMACOKINETICS AND PHARMACODYNAMICS* 
 
 
5.1 Introduction 
 
Cis-diamminedichloroplatinum (cisplatin) is a commonly used anticancer drug 
with a broad spectrum of activity against malignant solid tumors, including lung, head 
and neck, bladder, germ cell, ovarian, endometrial, and cervical cancer.2,4  Dose-limiting 
side effects such as renal tubular dysfunction, peripheral neuropathy, and ototoxicity, 
typically occur with conventional 3-weekly or 4-weekly regimens of cisplatin.4,58  
Hydration therapy has been incorporated into cisplatin treatment; however, 
approximately one-third of patients still show signs of acute renal toxicity.37,59,60 
Although cisplatin-induced toxicity is dose-dependent, the individual susceptibility to 
side effects varies considerably.  Previous studies have revealed significant relationships 
between cisplatin pharmacokinetics and the likelihood of drug-related side effects.4,61  
Hence, identification of factors that are associated with the clearance of cisplatin could 
aid in predicting or adapting appropriate, individualized doses of this agent. 
 
In our previous studies, we identified OCT2 as a primary regulator of cisplatin 
transport into human cells in vitro. In vivo we confirmed the role of OCT2 in mice 
lacking the mouse orthologue transporters Oct1 and Oct2. After cisplatin administration, 
mice deficient for Oct1 and Oct2 displayed a significantly lower urinary platinum 
excretion and did not display obvious signs of renal toxicity when compared to wildtype 
mice. The aims of the present study were to assess the association of variation in the gene 
encoding OCT2 (SLC22A2) with the disposition of cisplatin in adult Caucasian cancer 
patients. We hypothesize that functional changes in OCT2 will result in different toxicity 
profiles in patients carrying variant OCT2.  
 
 
5.2 Materials and Methods 
 
 
5.2.1 Materials  
 
SLC22A2 primers were custom made by the Hartwell Center (St. Jude Children’s 
Research Hospital, Memphis, TN).  The ExoSAP-IT reagent was obtained from USB 
Corporation (Cleveland, OH). 
 
 
5.2.2 Clinical studies 
  
All patients eligible for the study had a confirmed diagnosis of a malignant solid 
tumor, and were between the ages of 18 and 75 years.  Eligibility criteria have been 
documented in detail previously.62  The study protocols were approved by the Erasmus 
Medical Center review board (Rotterdam, The Netherlands), and all patients provided 
informed consent prior to enrollment. Cisplatin powder (Pharmachemie, Haarlem, The 
Netherlands) was dissolved in 250 mL of a sterile, hypertonic solution containing 3% 
(w/v) sodium chloride, and was administered as a 3-hour continuous intravenous infusion 
at doses ranging from 50 to 100 mg/m2 with treatment cycles repeated every week or 
every 3 weeks.  Cisplatin was administered either alone, or in combination with oral 
etoposide, irinotecan, oral topotecan, or docetaxel.  Prior investigation has shown that the 
disposition of cisplatin is unaffected by concomitant administration of these 
chemotherapeutic agents.63  Antiemetic prophylaxis consisted of a 5-hydroxytryptamine-
3 receptor antagonist in combination with dexamethasone. 
 
All patients had an Eastern Cooperative Oncology Group performance status 0 – 
2, had no previous anticancer therapy for at least 4 weeks, and had adequate 
hematopoietic (absolute neutrophil count, ≥ 1.5 × 109/L and platelet count, ≥ 100 × 
109/L), hepatic (total serum bilirubin, ≤ 1.25 × the upper limit of institutional normal 
values and serum transaminase levels, ≤ 2.5 × the upper limit of institutional normal 
values or ≤ 5 × in case of liver metastases), and renal function (normal serum creatinine 
and/or creatinine clearance, ≥ 60 mL/min) at the time of study entry. 
 
 
5.2.3 Pharmacokinetic analysis 
 
Blood samples were drawn from the arm opposite to the infusion site and 
collected in 4.5-mL glass tubes containing lithium heparin as an anticoagulant.  Blood 
samples were collected immediately before drug infusion, at 1 and 2 hours after the start 
of infusion, at 5 min before the end of infusion, and at 0.5, 1, 2, 3, and 18 hours after the 
end of infusion.  In a limited number of patients, additional samples were obtained at 1.5 
and 5 hour after the end of infusion.  Plasma was separated by centrifugation at 3000 g 
for 10 min, and 500-μL aliquots of plasma were immediately extracted with 1000 μL of 
neat ice-cold (-20°C) ethanol in a 2-mL polypropylene vial in order to obtain the fraction 
unbound platinum.64  The supernatant was collected by centrifugation at 23,000 g for 5 
min.  
 
Total platinum plasma concentrations were quantified after a 5-fold dilution of 
plasma in water containing 0.2% (v/v) Triton X-100 and 0.06% (w/v) cesium chloride.  
 
Complete urine collections were obtained for a period of 24-hours after the start 
of drug administration. Aliquots of 750 µL drug free nitric acid (0.2%) were added to 50 
µl of urine.  
 
Aliquots of 20 μL of processed ethanolic extracts, plasma or urine were 
eventually injected, in duplicate, into the atomic absorption spectrometer.  Samples were 
analyzed for platinum-containing species with a Perkin Elmer 4110 ZL spectrometer 
(Perkin Elmer) with Zeeman background correction using peak area signal measurements 
at a wavelength of 265.9 nm and a slit width of 0.7 nm.  Drug concentrations were 
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determined by interpolation on linear calibration curves constructed from drug-free 
matrices derived from healthy volunteers.   The lower limit of quantitations were 
established at 0.0300, 0.200 and 1.00 µg/mL platinum in ethanolic extracts, plasma and 
urine, respectively. The mean percentage deviation from nominal values (accuracy) and 
precision (within-run and between-run variability) of quality control samples spiked with 
known concentrations of cisplatin were always less than 15%. 
 
Individual platinum plasma concentration time profiles were analyzed by a 
noncompartmental method using WinNonlin version 5.1 (Pharsight, Inc., Mountain 
View, CA).  Plasma pharmacokinetic parameters assessed included peak concentration 
(Cmax), area under the plasma concentration-time curve extrapolated to infinity (AUC), 
and the systemic clearance (CL), which was calculated as dose divided by AUC.  
Standard noncompartmental evaluation has demonstrated that measures of systemic 
exposure to cisplatin are dose-proportional over the tested dose range.63 Therefore, values 
for Cmax and AUC were normalized to a dose of 75 mg/m2 without further correction. 
Urinary excretion was expressed as a percentage of the administered dose (in platinum 
equivalents) in the collection interval, whereas the apparent renal clearance (CLr) was 
calculated as the amount excreted in urine in the collection interval divided by the 
observed partial AUC within the same interval. 
 
 
5.2.4 Identification of SLC22A2 variants  
 
The genomic sequence of SLC22A2 was obtained from GenBank (accession 
number NM 003058), and primers were designed to span exons that contain 8 known 
non-synonymous, single-nucleotide polymorphisms (SNPs) identified previously in a 
Caucasian population,31 using Primer3 software.  These SNPs include sequence variation 
associated with amino acid changes at the following positions: Pro54Ser (exon 1), 
Phe161Leu, Met165Val, Met165Ile (exon 2), Ala270Ser (exon 4), Ala297Gly (exon 5), 
Arg400Cys (exon 7), and Lys432Gln (exon 8).  DNA was extracted from plasma, buffy 
coat, or whole blood using the QIAamp ultrasens virus kit and QIAamp DNA blood mini 
kit (Qiagen, Valencia, CA).  Optimal reaction and cycle conditions were determined for 
each amplicon in a 25-µL reaction volume.  Following PCR, samples were cleaned using 
ExoSAP-IT reagent and sequenced in the forward and reverse direction using the same 
primers used for PCR and Big Dye Terminator (version 3.1) Chemistry on Applied 
Biosystem 3730XL DNA Analyzers.  Sequencing analysis was performed using 
Sequencher software version 4.7 (Gene Codes Corporation, Ann Arbor, MI).    
 
 
5.2.5 Statistical considerations  
 
Group differences in median pharmacokinetic parameters of cisplatin as a 
function of human OCT2-variant status was evaluated using a Mann-Whitney U test. 
Changes in serum creatinine before and after cisplatin treatment in patients was assessed 
as a function of OCT2-variant status using a Wilcoxon’s signed ranks test.  Two-tailed P 
values of less than 0.05 were considered as statistically significant.  All statistical 
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calculations were performed using the software package NCSS version 2004 (Number 
Cruncher Statistical System, Kaysville, UT, USA). 
 
 
5.3 Results 
 
 
5.3.1 Cisplatin pharmacokinetics 
 
A pharmacokinetic analysis showed that the mean clearance for total platinum 
(0.738 L/h) and unbound platinum (29.2 L/h) in the studied patients was in the same 
range as previously reported in other predominantly Caucasian populations.2 The 
unbound clearance varied about 4-fold between patients (Table 5.1), and the observed 
variability was, in part, accounted for by sex (Fig 5.1), with men having a statistically 
significantly higher median unbound platinum clearance than women (P = 0.019).  
 
Out of the 8 non-synonymous SNPs evaluated, only one SNP (Ala270Ser; 
rs316019) was identified in this patient population, with an observed minor allele 
frequency of 7.6%.  However, none of the studied pharmacokinetic parameters were 
significantly associated with the presence or absence of this allele (P > 0.05).  For 
example, the unbound clearances in those patients carrying the reference or the 
heterozygous sequence were 29.5 ± 1.00 and 31.9 ± 2.89, respectively (P = 0.36) (Fig 
5.2A), whereas the values for renal clearance were 10.5 ± 0.628 and 9.50 ± 1.38, 
respectively (P = 0.55) (data not shown). The concentration time profiles were 
unchanged in patients carrying the reference and variant alleles (Fig 5.2B). This SNP was 
also not associated with the clearance of unbound cisplatin in males (P = 0.62) or females 
(P = 0.25) when analyzed separately.  
 
 
5.3.2 Genotype association with cisplatin induced toxicity  
 
Patients carrying a copy of this SNP experienced no change in serum creatinine 
after the first cycle of cisplatin treatment (P = 0.12), whereas serum creatinine 
significantly increased in patients carrying the reference sequence (P = 0.00009) (Fig 
5.3).  Three patients carrying the reference allele were considered to have changes in 
serum creatinine that were outliers in comparison to the rest of the cohort. One of the 
outliers may have been due to the use of diclofenac with cisplatin treatment. Diclofenac 
has been shown to interact with OCT2, ABCC2, and ABCC4 in vitro, although the 
interaction has not been completely determined.65,66 After the patient was placed on a 
different pain medication, serum creatinine levels returned to the range seen in the cohort 
of patients carrying the reference allele. This result could implicate a drug interaction at 
the site of renal tubular transport of cisplatin. Nonetheless, after removal of the three 
patients from analysis, changes in serum creatinine were still significantly higher in the 
reference group. 
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Table 5.1 Summary of pharmacokinetic parameters for cisplatin-derived platinum* 
 
 
Variable Median Mean ± SD Range 
Platinum dose (mg) 87.8 89.4 52-156 
Infusion duration (h) 3.02 3.25        2.67-4.73 
Total platinum    
   Cmax (µg/mL) 2.21   2.37 ± 0.450        1.49-3.66 
   AUC (µg·h/mL) 31.4 32.5 ± 9.75        9.60-54.2 
   CL (L/h) 0.632 0.738 ± 0.461      0.163-2.74 
   Urinary excretion (%) 31.1 31.4 ± 10.0        9.70-62.0 
   CLr (L/h) 9.51 10.2 ± 4.14        3.03-24.8 
Unbound platinum    
   Cmax (µg/mL) 0.947       0.890 ± 0.25      0.051-1.55 
   AUC (µg·h/mL) 2.75    2.61 ± 0.656      0.118-4.37 
   CL (L/h) 27.2  29.2 ± 8.39        16.8-75.4 
 
*Pharmacokinetic parameters were obtained with non-compartmental analysis, and normalized to 75 mg/m² 
cisplatin. 
Abbreviations: Cmax, peak concentration; AUC, area under the plasma concentration-time curve; CL, 
systemic clearance; CLr, renal clearance.   
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Figure 5.1 Sex Differences in Cisplatin Clearance 
 
Influence of sex on the clearance of unbound cisplatin. Each point indicates an individual 
patient. The horizontal lines indicate the mean. 
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Figure 5.2 Associations between Genotype and Cisplatin Clearance 
 
(A) Unchanged systemic clearance of unbound cisplatin in cancer patients as a function 
of SLC22A2 808G>T genotype status. Each point represents a patient and mean values 
are indicated by lines. (B) Concentration-time profile of unbound cisplatin as a function 
of SLC22A2 808G>T genotype status. Data shown as mean values ± standard error along 
with a curve fit from a 2-compartment model (lines). 
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Figure 5.3 Serum Creatinine Changes  
 
Changes in serum creatinine, a marker of nephrotoxicity, measured at baseline and after 
the first cycle of cisplatin treatment as a function of SLC22A2 Ala270Ser genotype. 
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5.4 Discussion 
 
 In this study we found that the human organic cation transporter OCT2 is 
involved in the toxicity associated with cisplatin treatment.  Through a pharmacokinetic 
analysis, we observed a high degree of interindividual variability in the clearance of 
cisplatin in a Caucasian population. No statistically significant associations were found 
between the pharmacokinetic parameters of cisplatin and a series of variants in the gene 
encoding OCT2 (SLC22A2).  However, patients carrying a variant allele in OCT2 were 
less likely to show increases in serum creatinine after the first cisplatin treatment cycle 
compared to individuals carrying the reference allele. 
We and others have previously determined that human OCT2 and its rodent 
orthologue may play a critical role in the cellular transport of cisplatin.28,40  Cisplatin-
induced nephrotoxicity typically occurs in the S3 segment of the renal proximal tubules,67 
where OCT2 is predominantly expressed on the basolateral membrane.68,69  This 
localization suggests that OCT2 may be a key regulator in the renal elimination of 
cisplatin.  Due to the high variability in cisplatin clearance found in our patient 
population, as well as the known extensive interindividual variability in the incidence and 
severity of drug-induced toxicity, we assessed a potential contribution to this 
phenomenon of known SNPs in the SLC22A2 gene.  Amongst 8 variants evaluated, only 
one SNP (Ala270Ser; rs316019) was found in the sample population.  This SNP was not 
associated with the plasma pharmacokinetics or the urinary excretion of cisplatin in these 
patients. However, this SNP was significantly associated with the serum creatinine levels 
in patients after the first cycle of cisplatin treatment. This observation is consistent with 
functional data obtained using heterologous expression models indicating that the 
functional activity of the Ala270Ser variant is lower than that of the OCT2 reference 
protein.70 This data also correlates with our previous findings in mice, indicating a lack of 
function of Oct2 may protect kidney cells from cisplatin induced damage without 
affecting plasma platinum concentrations. 
 
 These results implicate potential new mechanisms for the prevention of cisplatin-
induced nephrotoxicity by modulating the uptake of cisplatin into kidney cells. An OCT2 
inhibitor may be able to block the majority of cisplatin from entering kidney tubules, 
perhaps shunting the drug through other elimination pathways. Future studies in patients 
receiving cisplatin need to be performed to understand potential toxicities that may arise 
with the use of an inhibitor. This study further shows the important role OCT2 plays in 
the renal transport and toxicity of cisplatin.  
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CHAPTER 6. ORGANIC CATION TRANSPORTER 2 EXPRESSION IN HUMAN 
TISSUE AND TUMOR 
 
 
6.1 Introduction  
 
Organic cation transporter 2 (OCT2) is predominantly expressed on the 
basolateral surface of the renal proximal tubules with low level expression in the brain.25 
We have previously shown that OCT2 transports cisplatin, the most widely used 
anticancer agent, into the cell. In mice, a deficiency in Oct2 was able to protect kidney 
proximal tubules from severe tubular necrosis. Furthermore, patients carrying a variant in 
the gene encoding OCT2 which may decrease the function of the transporter, had a lower 
change in serum creatinine, a marker for kidney damage, than those patients carrying the 
reference allele. Taken together, these results could indicate an exciting new treatment 
regimen to reduce cisplatin-induced toxicity by blocking OCT2. However, preventing 
toxicity could pose possible problems for the anti-tumor efficacy of cisplatin. 
 
 To better understand the role OCT2 plays in the anti-tumor efficacy of cisplatin, 
we sought to evaluate the expression of OCT2 in human tumor cell lines, as well as, a 
panel of human tumor tissue. Currently there is little knowledge about the importance of 
OCT2 in human tumors, indicating that it may play a limited role. Therefore we 
hypothesize that OCT2 is not highly expressed in human tumor. 
 
 
6.2 Materials and Methods 
 
 
6.2.1 Real time PCR  
 
RNA and DNA from the NCI anti-cancer screening panel were provided by the 
National Cancer Institute tumor repository (Bethesda, MD, USA). RNA was reverse 
transcribed using SuperScript III first strand synthesis supermix for qRT-PCR 
(Invitrogen) according to manufacturer’s recommendations. Tissue plates containing 
cDNA from 48 human tissues and 96 human cancer tissues were obtained from Origene 
(Rockville, MD, USA).   Gene transcripts were quantified using SYBR Green PCR 
mastermix (Qiagen) and primers previously described.38 Reactions were carried out in 
triplicate unless otherwise stated as previously reported.5 Briefly, 25 µL volumes were 
used with the following PCR variables: 95ºC for 15 min then 40 cycles of 94ºC for 30 s, 
60ºC for 30 s, and 72ºC for 30 s, followed by dissociation cycles. Transcripts of each 
sample were normalized to the housekeeping gene, GAPDH.  
 
 
6.2.2 Identification of SLC22A2 variants  
 
The genomic sequence of SLC22A2 (accession no. NM 003058)  was obtained by 
Genbank and primers were designed as previously described.5  A single nucleotide 
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polymorphism (SNP) in SLC22A2 associated with an amino acid change at position 
Ala270Ser (exon 4) was evaluated. Optimal reaction and cycle conditions were 
determined for each amplicon in a 25 µL reaction volume. As previously described,5 PCR 
samples were cleaned with ExoSAP-IT reagent (USB Corporation, Cleveland, OH, USA) 
following PCR and sequenced in both forward and reverse directions using Big Dye 
Terminator (version 3.1) Chemistry on Applied Biosystems 3730XL DNA analyzers. 
Sequencher software version 4.7 (Gene Codes Corporation, Ann Arbor, MI, USA) was 
used for sequencing analysis.  
 
 
6.3 Results  
 
 
6.3.1 Expression of OCT2 in normal human tissue 
 
 Using real time PCR, OCT2 expression was confirmed in a panel of normal 
human tissue. As expected, the tissue with the highest expression was kidney tissue when 
compared to the other tissues (Fig 6.1). Low level expression was seen in a variety of 
other tissues; however not to the extent of the kidney expression.  
 
 
6.3.2 Expression of OCT2 in human tumor tissue 
 
 OCT2 expression was evaluated in cDNA human tumor tissue scan, as well as, 
the NCI 60 human tumor cell lines. OCT2 expression in the human tumor tissue again 
confirmed the presence of OCT2 in normal kidney and also showed low level expression 
in some kidney tumor types. The expression of OCT2 was absent in tumor from breast, 
colon, liver, lung, ovarian, prostate, and thyroid tissue, particularly when compared to the 
baseline expression in the kidney (Fig 6.2A). When looking at expression changes within 
tissues, colon and thyroid tumors appear to have higher expression than in the respective 
normal tissue (Fig 6.2B). 
 
 The NCI 60 human tumor panel again showed very low or absent expression 
levels of OCT2 (Fig 6.3). Two kidney cell lines, A498 and UO 31, were the only kidney 
lines expressing OCT2. Contrary to our tumor panel, one ovarian cancer cell line, SK OV 
3, expressed OCT2 higher than any other cell line. In addition to looking at OCT2 
expression, we evaluated the Ala270Ser SNP in the cell lines. Interestingly, we found a 
trend indicating that those cells lines carrying the variant allele had a reduced expression 
relative to those with the reference allele (Fig 6.4).  
 
 
6.4 Discussion 
 
 We have previously reported that OCT2 is a primary regulator for cisplatin 
transport and toxicity in renal cells, implicating possible new treatment options to reduce 
the occurrence of cisplatin-induced nephrotoxicity. Therefore, we sought to determine the  
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Figure 6.1 OCT2 Expression in Normal Human Tissue 
 
Expression of SLC22A2, normalized to the house keeping gene GAPDH, in (A) human 
normal tissue. SLC22A2 was predominantly expressed in kidney. Tissue plates containing 
cDNA tissues were used for real-time PCR analysis.  Data are shown as mean values 
(bars) of duplicate plates and expressed relative to values observed in normal human 
kidney, which was set to a value of 1. 
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Figure 6.2 OCT2 Expression in Human Tumor Tissue 
 
Expression of SLC22A2, normalized to the house keeping gene GAPDH, in human tumor 
samples (A) relative to the respective normal tissue and (B) relative to normal kidney.  
SLC22A2 was low to absent in tumor samples. Tumor plates containing cDNA were used 
for real-time PCR analysis.  Data are shown as mean values (bars) of duplicate plates and 
expressed relative to values observed in normal tissue and normal human kidney, which 
was set to a value of 1. 
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Figure 6.3 OCT2 Expression in the NCI 60 Tumor Cell Lines 
 
Expression of SLC22A2, normalized to the house keeping gene GAPDH, in human tumor 
cell lines. Data are shown as mean values (bars) ± SD (n = 3), expressed relative to 
values observed in the HCC 2998 cell line, which was set to a value of 1. 
 
 
 
 
 
 
 
56 
 
 
 
Figure 6.4 OCT2 Expression as a Function of Ala270Ser Genotype 
 
Correlation between mRNA expression of SLC22A2 (fold change versus the HCC 2998 
cell line) and SLC22A2 808G>T genotype in the NCI 60 cancer cell line panel.  
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contribution of OCT2 to the antitumor efficacy of cisplatin by evaluating the expression 
of OCT2 in tumor cells and human tumor tissue. In this study, we found that OCT2 is 
predominantly expressed in normal human kidney; however it has very low or absent 
expression in almost all tumor cells and tissue, in particular in those for which treatment 
with cisplatin is indicated, such as lung cancer and ovarian cancer. We did find one 
ovarian tumor cell line with high expression of OCT2 but, this expression is contradictory 
when comparing it to the ovarian tumor tissue we examined. Therefore this difference 
may be an artifact of the cell culture process. Experiments using the cDNA from the 
cancer plates and the NCI 60 tumor panel may not provide a comprehensive 
understanding of the expression of OCT2 in tumor cells. Studying expression in tumor 
samples, particularly before and after cisplatin treatment could fully elucidate the role of 
OCT2 in human tumors. Although our findings indicate a limited involvement of OCT2 
in human tumors, more elaborate investigations should be performed in the future to rule 
out any potential disruptions caused by an OCT2 inhibitor on cisplatin anti-tumor 
efficacy in patients.  
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CHAPTER 7. INTERACTION OF CISPLATIN WITH ABCC2 
 
 
7.1 Introduction 
 
 In previous studies, we demonstrated the importance of OCT2 in the transport of 
cisplatin through the basolateral site in renal proximal tubules. Mice lacking the organic 
cation transporter were protected from severe cisplatin-induced nephrotoxicity after 
treatment. Urinary platinum excretion of cisplatin in these animals was reduced to 
approximately 56% of the dose at 72 hours, whereas wildtype animals excreted almost 
100% of the dose. We also found a nonsynonymous SNP in OCT2, Ala270Ser, to be 
significantly associated with changes in serum creatinine after the first cycle of treatment. 
Patients carrying a variant allele exhibited a smaller percent change in serum creatinine 
compared to patients carrying the reference allele. This difference suggests that OCT2 is 
the primary regulator of cisplatin transport into the cell; however, the understanding of 
how cisplatin exits the cell via the apical membrane is poorly understood. Many 
transporters present on the apical membrane could be potential cisplatin transporters, for 
the purpose of this study we focused primarily on the multidrug resistance associated 
protein, ABCC2 (MRP2).   
 
 ABCC2 has been shown to be localized to the apical membrane of hepatocytes 
and renal proximal tubules.32 Previous reports have shown increased ABCC2 expression 
in cisplatin resistant cell lines and has been associated with cisplatin resistance in patients 
treated with cisplatin.23,34  In kidney cells, cisplatin can form glutathione conjugates 
before being eliminated. ABCC2 has also been implicated in the efflux of several 
glutathione conjugates,32 suggesting an important role for this transporter in the renal 
excretion of cisplatin. In this study we evaluated the contribution of ABCC2 to cisplatin 
transport, as well as, genetic variation in the gene encoding ABCC2. We hypothesize that 
ABCC2 will be a key transporter in the removal of cisplatin from kidney tubule cells. 
  
 
7.2 Materials and Methods 
 
 
7.2.1 Materials  
 
ABCC2 primers were custom made by the Hartwell Center (St. Jude Children’s 
Research Hospital, Memphis, TN).  The ExoSAP-IT reagent was obtained from USB 
Corporation (Cleveland, OH). 
 
 
7.2.2 Clinical studies 
  
All patients eligible for the study had a confirmed diagnosis of a malignant solid 
tumor, and were between the ages of 18 and 75 years.  Eligibility criteria have been 
documented in detail previously.62  The study protocols were approved by the Erasmus 
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Medical Center review board (Rotterdam, The Netherlands), and all patients provided 
informed consent prior to enrollment. Cisplatin powder (Pharmachemie, Haarlem, The 
Netherlands) was dissolved in 250 mL of a sterile, hypertonic solution containing 3% 
(w/v) sodium chloride, and was administered as a 3-hour continuous intravenous infusion 
at doses ranging from 50 to 100 mg/m2 with treatment cycles repeated every week or 
every 3 weeks.  Cisplatin was administered either alone, or in combination with oral 
etoposide, irinotecan, oral topotecan, or docetaxel.  Prior investigation has shown that the 
disposition of cisplatin is unaffected by concomitant administration of these 
chemotherapeutic agents.63  Antiemetic prophylaxis consisted of a 5-hydroxytryptamine-
3 receptor antagonist in combination with dexamethasone. 
 
All patients had an Eastern Cooperative Oncology Group performance status 0 – 
2, had no previous anticancer therapy for at least 4 weeks, and had adequate 
hematopoietic (absolute neutrophil count, ≥ 1.5 × 109/L and platelet count, ≥ 100 × 
109/L), hepatic (total serum bilirubin, ≤ 1.25 × the upper limit of institutional normal 
values and serum transaminase levels, ≤ 2.5 × the upper limit of institutional normal 
values or ≤ 5 × in case of liver metastases), and renal function (normal serum creatinine 
and/or creatinine clearance, ≥ 60 mL/min) at the time of study entry.   
 
 
7.2.3 Pharmacokinetic analysis 
 
Blood samples were drawn from the arm opposite to the infusion site and 
collected in 4.5-mL glass tubes containing lithium heparin as an anticoagulant.  Blood 
samples were collected immediately before drug infusion, at 1 and 2 hours after the start 
of infusion, at 5 min before the end of infusion, and at 0.5, 1, 2, 3, and 18 hours after the 
end of infusion.  In a limited number of patients, additional samples were obtained at 1.5 
and 5 hour after the end of infusion.  Plasma was separated by centrifugation at 3000 g 
for 10 min, and 500-μL aliquots of plasma were immediately extracted with 1000 μL of 
neat ice-cold (-20°C) ethanol in a 2-ml polypropylene vial in order to obtain the fraction 
unbound platinum.64  The supernatant was collected by centrifugation at 23,000 g for 5 
min.  
 
Total platinum plasma concentrations were quantified after a 5-fold dilution of 
plasma in water containing 0.2% (v/v) Triton X-100 and 0.06% (w/v) cesium chloride.  
 
Complete urine collections were obtained for a period of 24-hours after the start 
of drug administration. Aliquots of 750 µL drug free nitric acid (0.2%) were added to 50 
µl of urine.  
 
Aliquots of 20 μL of processed ethanolic extracts, plasma or urine were 
eventually injected, in duplicate, into the atomic absorption spectrometer.  Samples were 
analyzed for platinum-containing species with a Perkin Elmer 4110 ZL spectrometer 
(Perkin Elmer) with Zeeman background correction using peak area signal measurements 
at a wavelength of 265.9 nm and a slit width of 0.7 nm.  Drug concentrations were 
determined by interpolation on linear calibration curves constructed from drug-free 
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matrices derived from healthy volunteers.   The lower limit of quantitations were 
established at 0.0300, 0.200 and 1.00 µg/mL platinum in ethanolic extracts, plasma and 
urine, respectively. The mean percentage deviation from nominal values (accuracy) and 
precision (within-run and between-run variability) of quality control samples spiked with 
known concentrations of cisplatin were always less than 15%. 
 
Individual platinum plasma concentration time profiles were analyzed by a 
noncompartmental method using WinNonlin version 5.1 (Pharsight, Inc., Mountain 
View, CA).  Plasma pharmacokinetic parameters assessed included peak concentration 
(Cmax), area under the plasma concentration-time curve extrapolated to infinity (AUC), 
and the systemic clearance (CL), which was calculated as dose divided by AUC.  
Standard noncompartmental evaluation has demonstrated that measures of systemic 
exposure to cisplatin are dose-proportional over the tested dose range.63 Therefore, values 
for Cmax and AUC were normalized to a dose of 75 mg/m2 without further correction. 
Urinary excretion was expressed as a percentage of the administered dose (in platinum 
equivalents) in the collection interval, whereas the apparent renal clearance (CLr) was 
calculated as the amount excreted in urine in the collection interval divided by the 
observed partial AUC within the same interval. 
 
 
7.2.4 Identification of ABCC2 variants  
 
The genomic sequence of ABCC2 was obtained from GenBank (accession no. 
NM 000392), and primers were designed to span exons that contain 7 known single-
nucleotide polymorphisms (SNPs) using Primer3 software.  These SNPs include 
sequence variation at the following positions: -1549 (5’-flanking), -1019 (5’-flanking, -24 
(5’-UTR), 1249 (exon 10), -34 (intron 26), 3972 (exon 28), 4544 (exon 32).  DNA was 
extracted from plasma, buffy coat, or whole blood using the QIAamp ultrasens virus kit 
and QIAamp DNA blood mini kit (Qiagen, Valencia, CA).  Optimal reaction and cycle 
conditions were determined for each amplicon in a 25 µL reaction volume.  Following 
PCR, samples were cleaned using ExoSAP-IT reagent and sequenced in the forward and 
reverse direction using the same primers used for PCR and Big Dye Terminator (version 
3.1) Chemistry on Applied Biosystem 3730XL DNA Analyzers.  Sequencing analysis 
was performed using Sequencher software version 4.7 (Gene Codes Corporation, Ann 
Arbor, MI).    
 
 
7.2.5 Real time PCR  
 
RNA and DNA from the NCI anti-cancer screening panel were provided by the 
National Cancer Institute tumor repository (Bethesda, MD, USA). RNA was reverse 
transcribed using SuperScript III first strand synthesis supermix for qRT-PCR 
(Invitrogen) according to manufacturer’s recommendations. Gene transcripts were 
quantified using SYBR Green PCR mastermix (Qiagen) and primers previously 
described.38 Reactions were carried out in triplicate unless otherwise stated as previously 
reported.5 Briefly, 25 µL volumes were used with the following PCR variables: 95ºC for 
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15 min then 40 cycles of 94ºC for 30 s, 60ºC for 30 s, and 72ºC for 30 s, followed by 
dissociation cycles. Transcripts of each sample were normalized to the housekeeping 
gene, GAPDH.  
 
 
7.2.6 Animal experiments 
 
 Adult (8-12 week old) male Abcc2 (-/-) (Taconic) mice were used along with 
age-matched male FVB wild-type mice. All animals were housed and handled in 
accordance with the Institutional Animal Care and Use Committee of St. Jude Children’s 
Research Hospital. Animals were housed in a temperature controlled environment with a 
12 hour light cycle and were given a standard diet and water ad libitum.  
 
Urinary platinum excretion of cisplatin was studied in animals after they had 
acclimated to metabolic cages 5 days prior to drug administration. Baseline urine samples 
were collected sixteen hours after the onset of light, and next, mice were given a single 
intraperitoneal (i.p.) injection of cisplatin at a dose 10 mg/kg. Urine was collected 4, 24, 
48, and 72 hours after administration, diluted with nitric acid (0.2%) and immediately 
analyzed for total platinum using flameless atomic absorption spectrometry. At the end of 
the study period, mice were euthanized and tissues harvested for histological 
examination.  
 
 
7.2.7 Histological evaluation of mouse tissues  
 
Mice were humanely euthanized and the following tissues were collected: 
adrenals, bone marrow, brain, heart, kidneys, large intestine, liver, lung, lymph node, 
pancreas, reproductive tract, salivary gland, skeletal muscle, skin, small intestine, spleen, 
stomach, thymus, and thyroid.  After collection, tissues were fixed overnight in 10% 
neutral-buffered formalin.  Next, the tissues were processed routinely, embedded in 
paraffin, sectioned (4 µm) and stained with hematoxylin and eosin.  Microscopic 
evaluation was performed by an experienced veterinary pathologist blinded to the 
composition of the groups.  Toxicities, including acute renal tubular necrosis, were 
scored as ‘absent’, ‘rare’, ‘mild’, ‘moderate’ or ‘severe’. 
 
 
7.3 Results 
 
 
7.3.1 Association of cisplatin pharmacokinetics and ABCC2 variants 
 
A pharmacokinetic analysis showed that the mean clearance for total platinum 
(0.738 L/h) and unbound platinum (29.2 L/h) in the studied patients was in the same 
range as previously reported in other predominantly Caucasian populations.2 
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All seven SNPs analyzed were present in this Caucasian population, however only 
one SNP was significantly associated with pharmacokinetic parameters. Patients carrying 
the variant allele for SNP -34 exhibited a higher unbound clearance of cisplatin than 
those patients carrying the reference allele (Fig 7.1A). We then analyzed haplotypes for 
the ABCC2 gene and found one haplotype, AGTGTTG, was associated with an increased 
unbound renal clearance (Fig 7.1B).  
 
 
7.3.2 Urinary platinum excretion and cisplatin induced toxicity 
 
 After cisplatin treatment, Abcc2 (-/-) mice had no significant difference in the 
cumulative platinum excretion when compared to wildtype animals (Fig 7.2). 
Futhermore, Abcc2 (-/-) mice experienced severe renal tubular necrosis like the wildtype 
animals (Fig 7.3).  
 
 
7.3.3 Expression of ABCC2 in human tumor cell lines 
 
 We next evaluated the expression of ABCC2 in the NCI 60 tumor cell line panel. 
We found ABCC2 expressed in a variety of tumor cell lines including, colon, lung, 
melanoma, and renal cell lines (Fig 7.4). When we evaluated the effect of ABCC2 
genotype on this expression we saw only one SNP (-1019) having a moderate effect on 
ABCC2 expression in these cell lines (Fig 7.5). However, the only difference is seen in 
the cell lines carrying a heterozygous variant, with the homozygous variant the same as 
the reference. This discrepancy suggests that it is most likely a chance finding with little 
biological relevance. 
 
 
7.4 Discussion 
 
 In this study we evaluated the role of ABCC2 in the excretion of cisplatin. In 
patients we found one SNP, -34 in ABCC2 that appeared to be associated with the 
unbound clearance of cisplatin. However, several of the other SNPs studied had a rare 
allele frequency too low to be able to characterize their role in cisplatin clearance. This 
SNP has also not been functionally characterized or been associated with the clearance of 
other drugs, including irinotecan and docetaxel.71,72 Our haplotype analysis also revealed 
one haplotype with potential importance to the unbound renal clearance of cisplatin. 
Again, this haplotype has not been reported to functionally impact the clearance by 
ABCC2 in patients treated with irinotecan.71 Furthermore, the -34 SNP is not present in 
this haplotype. As with the single SNP analysis, several of the haplotypes exhibited very 
low frequencies in this population, making it difficult to fully understand the importance.  
 
 No significant difference in urinary platinum excretion was seen in Abcc2 (-/-) 
and wildtype animals after cisplatin administration. Previous investigators have shown 
that Abcc4 is upregulated in Abcc2 (-/-) mice.73 This upregulation may indicate a 
compensatory mechanism between the two transporters. It would be interesting to  
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Figure 7.1 Associations between Genotype and Cisplatin Clearance 
 
Association between (A) ABCC2 -34 genotype (TT refers to the reference sequence, 
whereas TC is the heterozygous variant sequence) and the clearance of unbound cisplatin 
and (B) ABCC2 haplotype and the unbound renal clearance of cisplatin. Each symbol 
represents an individual patient and horizontal lines indicate mean values.  
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Figure 7.2 Urinary Platinum Excretion in Abcc2 (-/-) Mice 
 
Effect of Abcc2 deficiency on renal handling of cisplatin in mice. The cumulative 
excretion of cisplatin after drug administration (10 mg/kg; i.p.) was unchanged in the 
Abcc2 (-/-) mice compared to wildtype mice (n = 4/group). Data are shown as mean 
values; error bars represent ± standard error.  
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Figure 7.3 Histopathology of Abcc2 and Wildtype Kidneys 
 
Comparative cisplatin-induced nephrotoxicity in (A) wildtype and (B) Abcc2 (-/-) mice 
72 hours after administration of cisplatin (10 mg/kg; i.p.) from representative animals. 
Severe tubular necrosis, characterized by dilated tubules filled with necrotic tubular 
epithelial cells was observed in kidneys of both wildtype and Abcc2 (-/-) mice. 
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Figure 7.4 ABCC2 Expression in the NCI 60 Tumor Cell Lines 
 
Expression of ABCC2, normalized to the house keeping gene GAPDH, in human tumor 
cell lines. Data are shown as mean values (bars) ± SD (n = 3), expressed relative to 
values observed in the U251 cell line, which was set to a value of 1. 
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Figure 7.5 ABCC2 Expression as a Function of ABCC2 Genotypes 
 
Correlation between mRNA expression of ABCC2 (fold change versus the U251 cell line) 
and ABCC2 genotype in the NCI 60 cancer cell line panel.  
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evaluate the urinary platinum excretion in an Abcc2/4 (-/-) mouse model. Our results may 
also imply a species difference in ABCC2 substrate recognition. More studies need to be 
done to fully understand this mechanism.  
 
 ABCC2 was found to be expressed in a variety of tumor cell lines; however, 
ABCC2 genotype did not significantly affect the expression. The expression of ABCC2 in 
these cell lines may indicate a potential mechanism of cisplatin resistance. 
 
 In conclusion, this study suggests that ABCC2 may not play a significant role in 
the pharmacokinetics of cisplatin. Further investigations are necessary to understand the 
contribution other ABC transporters have to the renal elimination of cisplatin.  
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CHAPTER 8. SUMMARY AND CONCLUSIONS 
 
 
 The main objective of these studies were to:  A) elucidate the role of organic 
cation transporter 2 (OCT2) in the cellular uptake of cisplatin, B) determine the effects of 
OCT2 and ABCC2 expression and genetic variation on cisplatin pharmacokinetics and 
toxicity, and C) evaluate the role of OCT2 and ABCC2 in tumor sensitivity. It was 
hypothesized that OCT2 would be the primary regulator of cisplatin entry into renal 
tubule cells, whereas, ABCC2 would subsequently efflux cisplatin into the urine. 
 
 The studies shown here provide evidence for a strong interaction of cisplatin with 
human OCT2. Previous investigations were inconsistent in determining the substrate 
affinity for OCT2,28,29 therefore a new cell model expressing OCT2 was created. In this 
model cisplatin uptake was temperature dependent indicating an active transport 
mechanism. Also, cisplatin was able to almost completely inhibit the uptake of 
prototypical organic cation TEA. Furthermore, cells expressing OCT2 had increased 
intracellular accumulation of platinum and Pt-DNA adducts after incubation with 
cisplatin. These studies suggest an important role for OCT2 in the intracellular transport 
of cisplatin in vitro.  
 
 To fully understand the interaction, knockout mouse models were utilized to 
determine the role Oct2 plays in vivo. Using metabolic cages, total platinum was 
measured in urine to evaluate the urinary platinum excretion after cisplatin 
administration. In Oct1 and Oct2 single knockout mice, no difference in urinary platinum 
excretion was seen when compared to wildtype animals. The literature indicates an 
increased expression of mouse Oct1 in mouse kidney compared to human OCT1 in 
human kidney. Although previous studies have indicated inconsistent results determining 
the substrate affinity of Oct1 with cisplatin,27-29 the unchanged platinum excretion in 
these animals suggests transport by Oct1. Therefore, it may serve as a compensatory 
mechanism in the mouse kidney. Therefore, the Oct1/2 (-/-) mice would function as a 
more complete model in which to understand cisplatin pharmacokinetics. The urinary 
platinum excretion in Oct1/2 (-/-) mice was decreased by almost half (approximately 56% 
of the dose after 72 hours) when compared to wildtype animals. However, there was no 
significant difference in plasma platinum concentrations. Serum chemistry analysis and 
histopathology also indicated that wildtype animals suffered severe tubular necrosis while 
the Oct1/2 (-/-) did not. No other tissues were affected. These results suggest that 
cisplatin may be eliminated through an alternate mechanism in the knockout animals, 
perhaps with more platinum going through the liver without adversely affecting the 
tissue. It would be interesting to evaluate gene expression changes in the liver, to identify 
any changes in transporters that may cause an increase in cisplatin transport through the 
liver. Furthermore, evaluating the elimination of cisplatin through the liver by assessing 
the platinum content in liver and feces could provide valuable information into the 
alternate mechanisms involved in cisplatin clearance.  
 
 The association between cisplatin pharmacokinetics and genetic variation in the 
gene encoding OCT2, SLC22A2, in patients treated with cisplatin was evaluated. In a 
71 
 
Caucasian population one nonsynonymous single nucleotide polymorphism in exon 4, 
808G>T (Ala270Ser; rs316019), was identified. This SNP has been associated with 
decreased uptake in vitro, as well as, decreased clearance in patients receiving metformin, 
an OCT2 substrate.70 As with the knockout mice, there was no difference in cisplatin 
plasma concentrations between patients carrying the reference allele and those with the 
variant allele. However, a significant difference in the change of serum creatinine, a 
marker for renal toxicity, after the first cycle of cisplatin was apparent. Patients carrying 
the reference allele had a significantly higher change in serum creatinine indicating 
possible renal damage in contrast to those with the variant allele. These results 
correspond with the mouse data indicating that less cisplatin exposure to the renal tubule 
cells decreases the potential for damage. To the best of our knowledge, this is the first 
evidence suggesting that inherited genetic variation is contributing to interindividual 
variability in cisplatin-induced nephrotoxicity.  Even though this observation requires 
confirmation in a larger cohort of patients as well as further exploration in other ethnic 
populations, these findings are in line with those obtained in the Oct1/2 (-/-) mice.  They 
also suggest that a priori genetic testing could possibly be employed in order to identify 
patients, eligible for treatment with cisplatin, that may or may not be at increased risk to 
develop acute nephrotoxicity. 
 
 Collectively, our demonstration that OCT2 plays an important role in cisplatin-
related nephrotoxicity reveals a new host factor that contributes to enhanced 
interindividual variation in tolerability to this drug.   These findings might benefit future 
therapeutic interventions for cisplatin-containing regimens involving the use of specific 
inhibitors of OCT2. Ongoing studies have indicated the possibility of inhibitors blocking 
the uptake of cisplatin into the cell. This could mimic the effect seen in the Oct1/2 (-/-) 
mice, protecting kidney tubules from accumulating damage-inducing concentrations of 
cisplatin. It would be interesting to establish an equitoxic dose in the Oct1/2 (-/-) mice 
and determine the cisplatin concentrations in the kidney and liver at several time points. 
Also, it is important to determine if the use of an Oct2 inhibitor could allow for similar 
urinary platinum excretion and toxicity profiles in wildtype and xenograft mice compared 
to Oct1/2 (-/-) mice treated with cisplatin. This research could develop into exciting new 
therapeutic regimens to prevent cisplatin-induced toxicity. 
 
 The current work on the mechanistic basis of cisplatin-induced nephrotoxicity 
also opens up new avenues for further evaluation of pharmacologic approaches for 
renoprotection through targeting of OCT2.  Over the last few decades, numerous 
approaches have been reported to afford renoprotection during cisplatin treatment.7  
However, most of these approaches have not separately considered the possible 
implications on the anticancer actions of cisplatin in tumors, which is surprising 
considering the overlap and degree of similarity in the critical target genes for cisplatin in 
the kidney and tumor cell. As mentioned, cisplatin is a widely used anticancer agent. 
Therefore, to be able to determine new ways to prevent cisplatin induced nephrotoxicity 
we must understand the effect it would have on cisplatin’s anticancer efficacy. In a panel 
of human cancer tissues and the NCI 60 cancer cell lines, it was found that OCT2 is not 
highly expressed in human tumors, including lung cancer and ovarian cancer, in which 
cisplatin is routinely used. Therefore, OCT2 may play a limited role in the uptake of 
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cisplatin into tumor cells, indicating it predominantly only affects renal transport. Future 
investigation into OCT2 expression in human tumors, particularly before and after 
cisplatin treatment, would provide a more comprehensive understanding into the 
functional importance of OCT2 in tumors. The models used in these experiments do give 
some insight into the expression of OCT2; however, the samples were limited and did not 
cover all cisplatin-treated cancer. 
 
 These studies determined the prominent transporter in the kidney transporting 
cisplatin from the blood; but how cisplatin is excreted into the urine needed to be 
investigated as well. Previous literature indicated that ABCC2 could be a potential 
transporter for cisplatin. In the same Caucasian patients used in the OCT2 studies, 
ABCC2 variation was assessed in relation to cispatin pharmacokinetics. Only one SNP 
showed any significance with the unbound clearance of cisplatin. One haplotype was also 
associated with the unbound renal clearance of cisplatin. Interestingly, this haplotype did 
not contain the variant allele of the SNP identified, and also contained a variant that has 
been previously implicated in a reduced function for other compounds.71 The lack of 
association could be due to the low number of patients expressing the particular SNPs of 
interest. Next the urinary platinum excretion was evaluated, but there was no difference 
in Abcc2 (-/-) mice compared to wildtype mice. Abcc2 (-/-) mice have been shown to 
overexpress Abcc4, which may act as a compensatory mechanism for Abcc2. Therefore, 
more transporters, perhaps using an Abcc2/4 (-/-) mouse model, need to be evaluated to 
understand the complex mechanism involved in the excretion of cisplatin into the urine. 
 
 In conclusion, we have identified the primary cisplatin renal transport mechanism, 
and shown its significance in cisplatin-induced toxicity. These studies guide future 
investigations into new therapeutic interventions for the prevention of nephrotoxicity 
associated with cisplatin containing chemotherapy. 
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